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INTRODUCTION
The complement system plays an important role in the initiation of acute and chronic inflammation.

Activation of the corn-

plement cascade may lead to tissue damage by chemotactic attraction and changes in the activity of polymorphonuclear leukocytes
which may release damaging proteolytic enzymes, degranulation of

mast cells and complement-mediated lysis of tissue cells.

In

addition, complement activation may stimulate osteoclastic bone
resorption, the production of lymphokines and increased differen-

tiation of B-lymphocytes.

Destruction of connective tissue and

bone are prominet, features in periodontal disease and emphasi.ze
the potential importance of complement activation in this disease

process.
Evidence exists that complement activation occurs in perio-

dontal disease.

Native C3 and C4 are reduced in gingival fluid

compared to serum in patients with severe periodontal disease
(Schenkein and Genco 1977a, Attstrom et al. 1975).

Complement

activation may occur consequent to antigen-antibody reaction or
by several alternative means.

Cleavage of C3 in gingival fluid

by the alternative and/or classical pathways or by direct enzymatic conversion is suggested by the presence of the conversion

product C3c (Attstrom et al. 1975, Schenkein and Genco 1977a) and

C3d (Schenkein and Genco 1977b) in gingival fluid.

These previous studies indicate that complement cleavage

occurs in very severe periodontal disease.

These investigations,

however, were conducted only in patients with severe periodontitis.

Due to the small amounts of gingival fluid obtainable

from mildly inflamed tissues, no longitudinal studies of comple-

ment activation have been reported.

The new measurement tech-

nique utilizing filter paper strips presented in this manuscript
allows measurement of complement cleavage by crossed-immunoelec-

trophoresis from gingival fluid samples taken from areas of

minimal inflammation.

In addition, modification of this tech-

nique by the Master’s candidate allows the simultaneous measurement by of C3, C4, B and their cleavage products from a gingival
fluid sample as small as 0.2 ul.

This technique allows longitu-

dinal studies of complement cleavage in periodontal disease.

The human complement system is a principal defense mechanism
which acts to protect the host from foreign substances.

However,

activation of the complement system may also lead to damage of

host tissue and exacerbation of the inflammatory response.
extensive biologic

activities

The

of complement result primarily from

the cleavage products resulting from activation of the complement

cascade.

The complement system consists of a series of proteins

which can be divided into three major pathways: the classical,

the alternative activating, and the terminal pathways.
Classical

The classical pathway,

Pathwa

activated primarily by antigen-

antibody complexes (Hyslop et al. 1970), consists of a cascade of
alternating proteolytic cleavage and protein-binding reactions
with important host defense consequences.

Thus, its major func-

tion is to provide an amplification mechanism consequent to the

interaction of antigen with specific antibody.

Other substances,

such as C-reactive protein, an acute phase serum protein, also

cause activation of the classical pathway (Siegel et al. 1976,
Volanakis and Kaplan 1974).

The recognition unit of the classical pathway, Cl, is a

trimolecular complex consisting of Clq, Clr, and Cls (Lepow et
al. 1963).

Clq, which consists of six peripheral subunits con-

nected by fibrillar strands to a central core (Knobel et al.

1975, Shelton et al. 1972), recognizes the Fc portion of immuno-

logically complexed IgG
(Augener et al. 1971).

(IgGl, IgG2, IgG3

or IgM antibody

At least two IgG molecules in close

proximity or one IgM pentamer are essential for the binding of
Clq (Colten et al. 1968).

In the presence of calcium ions, this

binding is thought to induce a change in the conformation of Clr
(M011er-Eberhard 1977), causing a self-cleavage reaction that
activates Clr (Naff and Ratnoff 1968).

The activated Clr then

cleaves a peptide bond in Cls to reveal its enzymatically active
serine esteratic site.

The natural substrates of Cls in serum are C4 and C2, the

next two components in the classical cascade (Mller-Eberhard and
Lepow 1965).

Cleavage of C4 and C2 by Cls leads to-the formation

of the short-li.ved activated proteins, C4b and C2a.

Cl first

cleaves C4 into C4b and C4a with C4b attaching to the immune

complex (Law et al. 1980).

Cls then cleaves C2 into the larger

C2a and the smaller C2b fragment (Kerr 1980) with C2a binding to

the attached C4b.
of Mg

++,

This complex, C4b, C2a, formed in the presence

functions enzymatically as the classical pathway C3

convertase which cleaves C3 into two fragments, C3a and the
larger C3b.

The classical complement system is controlled by a variety
of naturally occurring biochemical regulators present in serum.
Cl activity is balanced by the glycoprotein Cl inhibitor (Cl INH)

(Ratnoff and Lepow 1957), which forms a stoichiometric complex
with the active sites of both Clr and Cls.

This abrogates their

enzymatic activity and causes the dissociation of Cir and Cls
from antigen-antibody-Cl aggregates (Sim and Reboul 1981).

Clq

inhibitor has recently been described as physically binding to
Clq and blocking its activity (Ghebrehiwet 1981).
C4 is inactivated by two plasma proteins acting together.
C4 Binding Protein (C4BP) acts as a cofactor for the degradation

of C4b by the enzyme I (C3b inactivator, Fujita et al. 1978).

When bound or soluble C4b is complexed with C4BP, it is subject

to cleavage by I (Gigli et al. 1979, Nagasawa et al. 1980, Press
and Gagnon 1981).

ting C4b.

Serum proteases act to release C4c, inactiva-

In addition, the C4b,C2a complex is inherently un-

stable and dissociates rapidly.

Alternative Activating Pathway
The alternative activating pathway of complement was postulated in 1954 by Louis Pillemer based on observations of serum
proteins active in early host defenses against bacteria and

viruses in the absence of antibodies (Pillemer et al. 1954).

Specific immunity is therefore not required for the activity of
the alternative activating pathway (G6tze and Mller-Eberhard

1976).

The initiation of the enzyme cascade by certain micro-

organisms and mammalian cells is dependent on the chemical com-

position of their cell surface rather than on the formation of

immune complexes.

The activators of the alternative activating

pathway of human complement include a variety of microbial polysaccharides such as lipopolysaccharides from Gram negative bacteria

(Marcus et al. 1971),

teichoic acid from pneumococci

(Winkelstein and Tomasz 1978), and zymosan from yeast (Pillemer

et al. 1954).

In addition, this complement pathway has been

shown to inactivate many viruses (Hirsch et al. 1980, Mills et

al. 1979, Welsh 1977) and to kill a number of helminthic and

protozoan parasites (Santoro et al. 1979) in the absence of
antibody.

However, antibody-dependent activation of the alterna-

tire activating pathway has been described for immune aggregates
of certain IgG and IgA subclasses, and with aggregates containing

IgD and Ig,E (Reid 1983).

Also, certain immune complexes have

been shown,to initiate the alternative activating pathway .in the

absence of ’classical pathway components Cl and C4 (Edwards et al.

1980).
The initiating event in the alternative activating pathway

of complement involves the formation of a priming C3 convertase,

C3,Bb formed by the interaction of C3 (which has undergone a

spontaneous hydrolysis of a thioester bond) with B to form C3,B
which is then cleaved by the enzyme D in the presence of Mg ++ to

yield C3,Bb (Fearon and Austen 1975).

This occurs continually at

a slow rate in plasma and generates small amounts of C3b by the
enzymatic action of C3,Bb on C3.

Initiation of the amplification

loop of the alternative activating pathway is determined by the

attachment of C3b to an activating surface.

In the presence of an activating surface, C3b covalently

attaches to it and is therefore less susceptible to the regula-

tory proteins.

B then binds to C3b in the presence of Mg

++.

D

(proactivator convertase), a serine esterase present in serum

only in its active form with no known specific inhibitor, then
cleaves the bound B into Ba, which is released, and the larger Bb

(Lesavre and Mller-Eberhard 1978).
lar complex with C3b, C3b,Bb.

Bb forms a labile bimolecu-

P (properdin) is adsorbed to the

C3b,Bb complex from the serum and results in stabilization of
that complex (Medicus et al. 1980), with a five-fold increase in
its i__n yitro half-life (Fearon and Austen 1975).

The formation

of C3b,Bb, the C3 or "amplification" convertase, is the major

step in the. activation of the alternative activating pathway.
acts to cleave C3 into C3a and C3b.

It

Bound C3b may then recruit

the alternative activating pathway components, B, D, and P to

assemble more C3b,Bb complexes, creating many more molecules of
C3 convertase.

The C3b-dependent C3 convertase is also capable

of amplifying C3 cleavage initiated by the classical pathway.

The protein B contains the proteolytic site for C3 cleavage.
This activity is partially expressed in the C3,Bb complex (initiation loop) and is fully exposed in the C3b, Bb complex (activation loop, Fearon et al. 1973, Gtze and Mller-Eberhard 1976,

Medicus et al. 1976).

This accounts for the differences in the

activity of the two alternative activating pathway C3 conver-

tases: one resulting in continuous, low-grade production of C3b,
and the other incorporating the priming C3b with subsequent

amplified cleavage of C3.

In the absence of an activating surface, the regulatory
proteins dominate and no amplification is achieved.

The C3b, B

and C3b,Bb complexes are dissociated by H (beta-IH), a serum
glycoprotein that competes for the B binding site on bound or

free C3b (Fearon and Austen 1977).

I (C3b inactivator), an

endopeptidase, then cleaves the C3b complexed with H to form

inactive iC3b (Law et al. 1979, Mller-Eberhard and Schreiber

1980, Pangburn et al. 1977), destroying the hemolytic and immune
adherence reactivity of C3b. iC3b is susceptible to degradation
by other proteases (trypsin, plasmin and leukocyte elastase
(Johnson et al.. 1976, Taylor et al. 1977)), generating C3c (in
fluid phase) and C3d (which remains bound).

C3c may then be

cleaved to form C3e.

The competition between B and H for C3b determines whether

or not the alternative activating pathway is triggered (Fearon
and Austen 1977, Kazatchkine et al. 1979).

This is decided by

the presence or absence of certain cell membrane constituents
(activators of the alternative pathway) which protect C3b from

inactivation and block the active dissociation of P,C3b,Bb by the
regulatory proteins.

For example, C3b with no activator surface

binds H with almost one hundred-fold greater affinity than it
binds B (Kazatchkine et al. 1979).

Competition between B and H

for bound C3b is influenced by the amount of membrane sialic

acid, heparin, and C3 receptor protein.

In addition, the appropriate activating surface must be
close enough to the C3b molecule for attachment to occur before

the metastable binding site on C3b decays.

The C3b receptor of

human erythrocytes, polymorphonuclear leukocytes (PMNs), mono-

cytes, and B-lymphocytes strongly binds to C3b and exhibits Hlike activity. These receptors, therefore, regulate the alterna-

tive activating pathway by inhibiting formation of the C3 amplification convertase (Fearon 1979).

Terminal Pathway
The C3 convertases of both the classical and alternative

activating pathways of complement become C5 cOnvertases by binding C3b.

This binding exposes active sites on C2a and Bb,

respectively, allowing C4b,C2a,C3b (Cooper and M011er-Eberhard
1975) and activator-bound C3b,Bb,C3b sta LuilizeuA

Dy

co

identically to split one bond in the alpha-chain of C5.

act

This

last proteolytic step of the complement pathways yields the
smaller C5a (Hugli 1975) which is released and C5b which binds to

the alternative pathway activator or to the immune complex.

The

membrane attack complex which follows is a rapid non-enzymatic

process common to both pathways.

C5b combines with C6 (Yamamoto

and Gewurz 1978) and C7 (Podack et al. 1978) to form the trimo-

lecular complex C5b,C6,C7 which intimately attaches to targetcell lipid membrane via the generation of hydrophobic forces

(Monahan and Sodetz 1981).

C8 then binds to the attached complex

and forms a structural pore through the lipid bilayer of the

membrane permitting bidirectional ion and water passage.

C9

-I0combines with the C5b,C6,C7,C8 complex and acts as an acceler-

ating factor leading to osmotic lysis and death of the target

cell. Cell lysis is characterized by distinct 100A circular
lesions.

This final membrane attack complex is stable and has a

molecular weight of 1,000,000 daltons (Kolb and Mller-Eberhard

1975).
The regulators of this terminal pathway act by inserting
into the membrane attack complex as it forms, preventing the

attachment of the complex to the target cell membrane.

These

regulators include low density lipoproteins (Lint et al. 1977),

Anti-thrombin III, and the

$

protein of normal serum (Podack et

al. 1978b).

Sensitivity of bacteria to the lytic action of the membrane
attack complex appears to be related to the "-’LL,+/-UI

wall.

u-

ne-’- cell

Most gram-negative organisms can be killed by antibody and

complement, but most gram-positive organisms are resistant.

Biologi_c Activities o__f Complement
The activation of the complement cascade induces many of the

phenomena characteristic of inflammation.

This response contri-

butes to host defenses by protecting against foreign substances,
but may also be responsible for damage to host tissues.

Most of

the biologic activities result from the release of limited proteolytic cleavage products formed by the complement cascade.

Others are caused by’ the binding of complement cleavage products

-II-

to other cells, such as macrophages, PMNs, lymphocytes, erythro-

cytes, and platelets.
Effect on _the vasculatur_e.

re.sults

Increased vascular permeability

from two potent stimulators of inflammation, C3a (Hugli

1975, Hugli and M011er-Eberhard 1978) and C5a (Gerard and Hugli
1979, Gerard et al. 1981).

These low molecular weight anaphyla-

toxins (generated by both the classical and alternative activa-

ting pathways of complement) cause degranulation and release of

histamine from human mast cells and basophils by non-lytic mech-

anisms, resulting ultimately in smooth muscle contraction (Gerard
et al. 1980) and increased vascular permeability.

In fact, C3a

and C5a elicit an immediate edema and erythema reaction when

injected into human skin even at extremely low concentrations.
C4a has also been shown to exhibit anaphylatoxic activity (Gorski

et al. 1979).

The vascular permeability effects of C3a, C4a, and

C5a are controlled by anaphylatoxin inactivator, a carboxypepti-

dase present in human serum that removes the carboxy-terminal
arginine residue (Bokish and Mler-Eberhard 1970).

Changes in

vascular permeability (a kinin-like activity) also result from a

vasoactive peptide cleavage fragment of C2 (Klemperer et al.

1969, Becker et al. 1974).

Effect

ol! granulocYtes.

The accumulation of leukocytes is

characteristic of inflammation and is a prime defensive mechanism
of the host.

C5a, a chemotactic factor produced by proteolytic

cleavage of C5, stimulates directed movement of neutrophils,
basophils, eosinophils, and monocytes (Ward and Newman 1969).

-12-

C3b,Bb and Ba (Hadding et al. 1978), formed by the alternative
activating pathway, have been shown to be chemotactic for neutrophils (Takahashi et al. 1980).

In addition, the decay product of

(Ward et al.

C5b,C6,C7 exhibits chemotactic activity in

1966). Complement-derived chemotactic factors have been shown to
have potent in v_iy_Q activity.

They have

been

isolated from

inflamed tissues and local injection of these factors causes an
accumulation of leukocytes (Ward and Becker 1977).

present in serum is able to destroy

A factor

the complement-derived

chemotactic activity (Kreutzer et al. 1979).

The chemotactic

activity of C3a is controversial (Damerau 1978, Rother 1972).
A systemic leukocyte mobilizing effect has been shown for
C3e, leading to leukocytosis by stimulating PMN release from bone

marrow (Ghebrehiwet and Mller-Eberhard 1979).

C3e, therefore,

increases the pool of responding cells in inflammation.

In addition to the chemoattraction of leukocytes to sites of
complement activation, several complement cleavage products lead

to changes in the activity and responsiveness of leukocytes.

C3b

has been shown to increase neutrophil oxidative metabolism
(Goldstein et al. 1976) and also to permit subthreshold amounts
of immunoglobulin to cause lysosomal enzyme release.

A cleavage

fragment of C5 causes aggregation of granulocytes (O’Flaherty et

al. 1977a),

reflected by an increase in their adhesiveness

(Craddock et al. 1977), which may serve a role in margination, an
early inflammatory response (O’Flaherty et al. 1977b).
been shown in

_v

C5a has

to stimulate the secretion of lysosomal

enzymes from neutrophils (Becker et al. 1974, Goldstein and
Weissman 1974).
Several complement components are also active in promoting

immune adherence and opsonization.

C3b-coated target cells or

immune complexes have been shown to bind to certain cells which

possess specialized membrane receptors for C3b.

PMNs, macro-

phages, monocytes, eosinophils, and lymphocytes all possess
stable surface receptors for C3b.

This immune adherence through

the C3b receptors facilitates the involvement of these cells in

the inflammatory response (Gigli and Nelson 1968). When opsonized

by C3b, one hundred times more bacteria bind to a neutrophil
membrane than when bacteria are opsonized by IgG alone (Menzel et

al. 1978).

Although binding appears to be strongly promoted, C3b

alone does not seem to induce phagocytosis.

However, a synergy

exists between IgG and C3b in IgG-mediated phagoctosis (Fearon

1979).

C4b also promotes the immune adherence phenomenon (Cooper

1969) and CSb may act to increase the phagocytosis of C3b-opsonized ba ct e r i a.

Effec.t

o_/!

monuclear cells.

Bb activates macrophages,

causing spreading of peripheral monocytes (Gtze et al. 1979) and
migration inhibition.

In addition, C3b has been shown to cause

IgG-independent lysosomal enzyme secretion by cultured guinea pig
and murine peritoneal macrophages (Schorlemmer and Allison 1976).

Evidence exists that activated mouse macrophages bind and ingest

C3b-coated particles in the absence of IgG (Bianco et al. 1976).

-14-

Macrophages also have iC3b receptors, thought to promote attachment but not phagocytosis.

The macrophage C3b receptors may

serve a critical role in presentation of antigen to antibodyproducing cells.

B-lymphocytes (Ross et al. 1973), peripheral

blood monocytes (Ehlenberger and Nussenweig 1975), and macro-

phages (Reynolds et al. 1975) bear receptors for C3d which may be
involved in immune adherence.
Complement cleavage products from both complement pathways

influence lymphocyte activity.

The adherence reaction of C3b-

bearing particles stimulates the secretion of chemotactic lymphokines by B-lymphocytes (Sandberg et al. 1975), and promotes the

development of B-cells into memory cells (Klaus and Humphrey
1977) and antibody-secreting cells (Lewis et al. 1977). C3c and
C3d have been recently shown to inhibit T-lymphocyte proliferation by antigen (Schenkein and Genco 1979).

Indirect evidence exists to suggest that the differentiation
of lymphocytes is affected by C3b. /d! 3, the depletion of C3

prevents the development of the primary response to T-dependent
antigens, thought to be mediated through C3d receptors present on

some B-lymphocytes (Pepys 1974).

Q_ effect..s.

Complement activation also leads to irrever-

sible damage to biological membranes through the common terminal

pathway.

The membrane attack complex (C5b,C6,C7,C8,C9) does not

involve specific receptor binding and leads to uptake of salt and
water by the target cell with ultimate lysis.

This occurs in

target bacterial or tumor cells, but can also cause damage-to

-15-

host tissues by the innocent bystander phenomenon or through
autoimmune mechanisms.

Complement-dependent prostaglandin-mediated bone resorption
has been shown when the bone tissue has been incubated with anti-

serum or heterologous serum (Raisz et al. 1974).
has recently been shown that C3b,

In addition, it

iC3b and C3c induce human

mononuclear phagocytes to synthesize and secrete prostaglandin

(Rutherford and Schenkein 1983).
C3b may inhibit cross-linking and lattice formation of
immune complexes, resulting in the solubilization of large immune

complexes.

These solubilized complexes

cad

neither bind cells

nor activate complement (Takahashi et al. 1980).
Other complement products have a variety of effects inclu-

ding: C5 split products may trigger the extrinsic clotting path-

way (Muhlfelder et al. 1979), C4b may be important in virus
neutralization (Daniels et al. 1969).
Complement and Inflammatory Disease
Activation of the complement cascade results in a variety of

biologic effects.

These include: i) irreversible damage to bio-

logic membranes, 2) deposition of molecules on the surface of
particles to opsonize and to promote clearance, and 3) formation
of potent mediators of the inflammatory response.

These activi-

ties, although beneficial to the host, also possess an inherent
potential for coincidental damage.

The complement system has,

therefore, been implicated in a variety of inflammatory diseases.

-16-

Direct cytotoxic injury involves antibody reacting directly
with a cell and activating the complement enzyme cascade.

Inflammatory mediators are released and the cells are damaged.
Autoimmune hemolytic anemia results from this process with the

development of antibodies to erythrocyte antigens.

Nephrotoxic

nephritis is also thought to result from complement-mediated

cytotoxic reactions.
Circulating immune complexes induce tissue injury through
activation of the complement system.

These antigen-antibody com-

plexes deposit in tissues that have no antigenic relationship to

the antibody, such as renal glomeruli or vascular endothelium and
initiate complement cleavage and the consequent inflammatory

sequelae.

In instances of antibody excess, Arthus-type vascu-

litis reactions result.

Farmer’s lung (hypersensitivity pneu-

monitis) is an example of this phenomenon, with inhaled antigens
combining with antibodies in the alveoli, activating complement,
and inducing an inflammatory response.

Antigen excess results in

"serum sickness" type reactions with immune complex deposition
and complement activation culminating in glomerulonephritis,

arthritis, and vasculitis.

This occurs following exposure to

sensitizing antigens in drugs or foreign serum.

The local ization

of the immune complexes and inflammatory sequelae depend on the

chemical and physical nature of the antigen-antibody complexes in

addition to the properties of the target tissue (Cochrane 1971).
Immune complexes of IgG I,

IgG2, IgG 3, or IgM are known to acti-

vate the classical pathway of complement.

However, in immune

-17-

_

complex disease, the alternative pathway of complement is thought

to participate at least through its amplification loop.

C3b

production by the classical pathway leads to alternative pathway
C3 convertase generation.

vivo, C3, P and H deposits are

found in addition to immune complexes in the glomeruli (Wyatt et
al. 1 97 9).
Autoantibodies formed against soluble antigens to which they

are continually exposed, give rise to a constant supply of immune

complexes and to lesions similar to serum sickness.

In Systemic

Lupus Erythematosis (SLE) with renal dysfunction, complexes of
DNA and other nuclear antigens with IgG and complement have been
visualized in the glomeruli of patients by using immunofluores-

cent techniques (Koffler et al. 1971).

Electron microscopic

studies have confirmed the presence of "lumpy-bumpy" immune corn-

plex deposits on the epithelial side of the glomerular basement
membrane (Koffler.et al. 1971).

Further evidence exists to

solidly link complement cleavage with SLE.

The active phase of

SLE (increased clinical severity of the disease) has been associated with a drop in total serum complement levels attributed to

cascade activation by immune complexes in the circulation and in
the kidneys (Williams and Law 1958, Ellis and Felix-Davies 1959).

In longitudinal observations, Schur and Sandson (1968) observed
decreased complement levels in advance of clinical exacerbation.

In fact, clinical symptoms, immune complex concentrations, and
complement levels appear to be strongly associated.

Patients

with persistently depressed C3 had more symptoms of nephritis

-18-

(Stastny and Ziff 1968), associated with cold-insoluble immune
complexes (Stastny and Z iff 1969) and circulating antibodies to
nuclear antigens (Tojo and Friou 1968, Townes et al. 1963) which

activate complement.

Therefore, it is hypothesized that circula-

ting immune complexes deposit beneath the glomerular basement

membrane,

response.

activate complement

and

incite

an inflammatory

This process may be compounded by the phenomenon of

defective immune complex solubilizing capacity observed in sera
from patients with active SLE (Sakurai et al. 1982).

The most consistently depressed complement component in SLE

serum is C4 (Perrin et al. 1973).

However, elevated serum fennels

of Ba and reduced levels of B have been observed during periods
of intense classical pathway activation (Hunsicker et al. 1972,

Perrin et al. 1975).

These alternative pathway cleavage products

have been seen chiefly in cases where the classical pathway has
been activated (Perrin et al. 1973, Hunnsicker et al. 1972);

serum B depressions have been observed in sera with already
depressed C4 (Perrin et al. 1973), suggesting the primary role of
the classical pathway and an amplification role for the alternatire pathway.

Similar mechanisms have been implicated in a

variety of diseases such as polyarteritis nodosa with inflam-

matory lesions in the blood vessel walls.
Complement serum depressions have been associated with other
systemic rheumatic diseases including mixed IgG-IgM cryoglob-

ulinemia (Riethmuller et al. 1966, Wilson et al 1977), Walden-

strom’s macroglobulinemia (Glovsky and Fudenberg 1970), arthritis
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with cutaneous vasculitis (McDuffie et al. 1973), and polyarteritis (Gocke et al. 1970).

Changes in the complement catabolic

rate have also been associated with disease processes, such as
Ankylosing Spondylitis (Brinch 1982).
Local formation of immune complexes with consequent comple-

ment cleavage leads to the development of inflammatory disease
within a specific organ or extravascular site.

For example,

analysis of synovial fluid, cerebral spinal fluid, or pleural
effusions may reveal immunopathologic processes not necessarily

detectable in peripheral blood.

Rheumatoid arthritis (RA) is

though to have an immune complex-mediated inflammation ,centered

primarily in the intra-articular region.

The immune, complexes

present in RA consist of Rheumatoid Factor (IgG, IgA, and IgM

immunoglobulins) in combination with IgG antigen or self-associated aggr.egates of IgG rheumatoid factors (Winchester et al.

1970).

These complexes (especially IgM) activate complement

(Townes and Marcus 1972, Tanimoto et al. 1975) through the classical pathway and then are phagocytized by the infiltrating poly-

morphonuclear leukocytes with consequent tissue damage.

to support this concept of RA etiology is strong.

Evidence

Immunoglobu-

fins, Clq, C4, and C3 have been found within the intra-articular
phagocytic cells (Hollander et al. 1965) and deposited in the
synovial lining tissue when examined with immunofluorescence

(Britton and Schur,

1971).

In addition,

the RA synovium is

heavily infiltrated with mononuclear cells, including macrophages
(Ishikawa and Z iff 1976) and many plasma cells with a high rate
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of synthesis of immunoglobulins, including rheumatoid factor.

Rheumatoid synovial tissue has been shown to synthesize many

complement components: C2, C3, C4, and C5 (Ruddy and Colten 1974,

Whaley 1980) and C2, B, D, P, I and H (DeCeulaer 1980).

There-

fore, within the synovium all the participants necessary for
complement-mediated immune complex-induced inflammation are pre-

sent.
Considerable additional evidence adds support to the impli-

cation of complement-fixing immune complexes in the pathogenesis
of rheumatoid arthritis.

Synovial fluid in RA patients has been

shown by several investigators to have depressed whole complement
levels (Pekin and Zvaifler 1964, Hunder et al. 1977).

Individual

complement components also are reduced in the synovial fluid of

these patients; depressed C4 levels are most consistent (Hunder
and McDuffie 1973).

Serum from RA patients may also have low

levels of C4, but most have normal or even elevated levels in

serum when rheumatoid vasculitis is not present (Franco and Schur

1971, Ruddy and Austen 1970, Versey et al. 1973).

In addition,

the few with decreased complement serum levels have more severe
disease and high rheumatoid factor titers (Ruddy and Austen 1970,

Vaughan et al. 1968).

Perrin et al. (1977) observed significant-

ly increased levels of breakdown products of C3, C4, and B in the

joint fluid from RA patients when compared with osteoarthritis
patients.

The parallel increase of C3d (Nydegger et al. 1977),

C4d and Ba levels in the RA patients suggest true activation of
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the complement system rather than a non-specific enzymatic break-

down in the synovial fluid.

C3 conversion was found in all

synovial fluids of sero-positive RA patients tested by Hunder et

al. (1977), with an accelerated functional catabolic and synthesis rate of C3 measured using radio-labelled C3 (Weinstein et al.

1972, Ruddy et al. 1975).

C3 levels in sero-positive RA were

shown to be decreased when measured by radial immunodiffusion

(Ruddy et al. 1969), crossed immunoelectrophoresis (Hedberg 1964)

or hemolytic titration (Ruddy and Austen 1970) methods.

Low

levels of both C2 and C4 suggest that the lowered synovial fluid
complement levels are due to classical pathway activation (Ruddy
and Austen 1970, Gabay et al. 1975).

Winchester et al. (1969) established a correlation between
the amount of immunoglobulin-containing complexes and the diminution of total hemolytic complement activity in synovial fluid

from patients with sero-positive R

Townes and Marcus (1972).

This was also confirmed by

In addition, it has been demonstrated

that complement proceeds to cytolytic completion in the RA joint

space.

Ruddy et al. (1971) found decreased C9 levels in joint

fluid and Dourmaskin and Patterson (1976) observed membrane le-

sions in synovial cells characteristic of the membrane attack

complex using electron microscopy.
Complement activation by the classical pathway thus appears
to be a factor in RA with intra-articular cleavage of C3, its

deposition in tissues with PMN phagocytosis and appearance of

cleavage fragments.

However, the alternative pathway components,
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B and P, have diminished levels in RA joint fluid and their
cleavage products also appear in these fluids (Zvaifler 1974,

Ruddy et al. 1975b, Lambert et al. 1975).

Increased catabolism

of B has been demonstrated in the serum of patients with RA

(Krick et al. 1978).

Kaplan et al. (1980), using radio-iodide

labelled C4 and B, concluded that the C4 fractional catabolic
rate was predominant over the B fractional catabolic rate.

He

found that the catabolism correlated significantly with rheumatoid factor, supporting the concept of RA as a systemic, extra-

vascular immune complex disease with rheumatoid factor immune

complexes playing a significant pathogenic role through the actiration of the classical complement pathway, with the alternative

activating pathway acting in an amplifying role.

However, Hunder

et al. (1979) showed that direct activation of the alternative

pathway in RA is also possible.

Using C4-deficient serum, he

observed complement cleavage induced by unidentified substances
in the sera and synovial fluid of RA patients.

The amount of

complement cleavage was approximately the same whether the classical pathway was operational or not.

Other investigators have

demonstrated that Type I and Type II collagen are able to induce
C3 and B conversion in both normal and C4-deficient serum, sug-

gesting a mechanism for the direct alternative pathway activation
in RA synovial fluid (Takahashi et al. 1975).

The alternative pathway has been shown to be active in a
number of other pathologic conditions.

Complement activation as

evidenced by hypercatabolism of serum C3 has suggested a role for
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complement in Ulcerative Colitis and Crohn’s Disease (Hodgson et

al. 1977), involving the activation of complement within the
inflamed gastrointestinal mucosa and sequestration of C3 in the
extravascular space.

Lake et al. (1979) observed abnormalities

of the alternative pathway (decreased serum P) in the serum of

patients at the time of diagnosis of inflammatory bowel disease,

especially regional enteritis and Crohn’s disease.

The classical

pathway appeared intact in this study.
Other diseases are characterized by aberrations in the alternative pathway.

Membranoproliferative glomerulonephritis and

partial lipodystrophy (Peters et al. 1972) have been associated
with a prolonged reduction in total serum hemolytic complement

(low serum C3 with normal CI, C4, and C2 (West et al. 1965)).

Investigators have described C3 Nephritic Factor present in the

serum of some of these patients (Spitzer et al. 1969).

C3 Neph-

ritic Factor is an IgG autoantibody capable of activating the

alternative pathway of complement by combining with and stabili-

zing C3b, B convertase (Fearon et al. 1975), therefore causing a
rapid consumption of C3.

Peters et al. (1972) examined 15

pa"

tients with this disease and found reduced levels of C3 and C7 in
the serum, with C3 breakdown products and C3 Nephritic Factor
also present.

In addition, C3 and immune complex deposits were

present in the kidneys.
Another disease, Paroxysmal Noctural Hemoglobinuria, has
also been linked to the activation of the alternative pathway.

It is an acquired disorder of erythrocyte membranes which
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heightens their susceptibility to complement-mediated lysis.

The

erythrocytes therefore have a shortened life span (Hinz et al.
1956).
In gram negative bacteremic individuals, decreased serum C3

levels have been associated with shock (McCabe 1973).

P, C3, C5,

C6, and C9 levels are lower in bacteremic individuals with shock

than in those not in shock.

Palestine and Klemperer

(1976)

observed circulating B cleavage products in normotensive bacteremic patients, despite the presence of normal or even elevated B

levels, suggesting involvement of the alternative pathway.
Complement an__d Periodontal Disease
Chronic inflammatory periodontal disease, the major cause of

tooth loss in adults, is characterized by infiltration of the

gingival tissues by inflammatory cells and loss of connective
tissue substance.

Page and Schroeder (1976) have described the

various stages of the progression of periodontal disease.

The

initial lesion, which occurs after a few days accumulation of

microbial plaque, is characterized by acute exudative vasculitis,
edema, loss of per ivascular collagen, and the presence of PMNs

intercellularly migrating through the gingiva into the sulcus.
PMNs are present in the progressing lesions, also.

The early

lesion, which develops within four to ten days of plaque accumulation, consists of a dense infiltrate of small lymphocytes and
other mononuclear cells, accompanied by degenerative change in

fibroblasts and continued loss of connective tissue substance.
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The established lesion, present in two to three weeks, reveals a

predominance of plasma cells,

and may remain stable for several

years, or progress to the advanced lesion.

The advanced lesion

is characterized by a loss of alveolar bone and periodontal

ligament,

many plasma cells, fibrosis, bone resorption and

destruction of the normal periodontal architecture.
Since the histopathologic features of periodontal disease

are similar to other chronic inflammatory disease processes which
involve the complement system, the potential role of the comple-

ment system in the initiation and progression of acute and chronic periodontal inflammation has been the subject of considerable

study.

Analyses of the exudate of periodontal lesions, gingival

fluid, have provided an avenue for examination of the complement

system.

Several investigators have confirmed that gingival fluid

is an altered inflammatory exudate.

This has been accomplished

by examining the proteins (Brill and Bronnestrom 1960, Mann and
Stoffer 1964, Weinstein and Mandel 1964, Schenkein and Genco

1977a), carbohydrates (Hara and L6e 196 9), ions (Krasse and
Egelberg 1962), and enzymes (Gustafson and Nilssen 1961, Frank
and Cimasoni 1972) present in gingival fluid and comparing them
with serum content.

However, studies of gingival fluid are

hindered by the small amounts which can be collected and by the
vast assortment of microbial and host-derived substances which
are present.

Complement components have been identified in gingival

fluid.

Shillitoe and Lehner (1972) observed concentrations of C3
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in gingival fluid which were somewhat less than those found in

serum.

Courts et al. (1977) noted the existence of a functional

complement system in the gingival fluid of patients with perio-

dontitis.

The authors reported that the addition of dental

plaque to gingival fluid led to Cl fixation and they determined
both

ci hemolytic activity and whole complement hemolytic activi-

Complement utilization appears to be associated with perio-

dontal disease.

Reduced levels of native C3 and C4 (Attstrom et

al. 1975, Schenkein and Genco 1977a) relative to other serum
proteins have been found in the gingival fluid obtained from

severe periodontal lesions.

Schenkein and Genco (1977a) observed

that native C3 in gingival fluid from diseased sites was approxi-

mately25% of the serum level while other serum components of
similar molecular weight existed at 80% of serum levels.

Activa-

tion of C3 in gingival fluid obtained from periodontal lesions

has been suggested by the presence of its cleavage products, C3c

(Attstrom et al. 1975, Schenkein et al. 1976, Schenkein and Genco

1977b) and C3d (Schenkein and Genco 1977b).

Patters et al.

(1979) reported a larger percent of C3 cleavage in gingival fluid
from inflamed sites when compared with healthy sites.

C4c, a

conversion product of C4 (Shiraishi and Stroud 1975) has been

observed in the gingival fluids of patients with juvenile perio-

dontitis (Schenkein et al. 1976) and in some patients with severe

rapidly progressive periodontitis (Schenkein and Genco 1977b).
The cleavage product of B, Bb, has been detected in the gingival
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fluid from severely diseased sites

Schenkein et al.

1976,

(Attstrom et al.

1975,
In all

Schenkein and Genco 1977b).

patients examined in these studies, no complement cleavage pro-

ducts were observed in serum.
Additional indirect evidence exists to support the concept
of complement cleavage in periodontal disease.

Extracts of gin-

gival tissues from patients with periodontitis were observed to
be chemotactic for monocytes (Okada and Silverman 1979).

was not true for tissue from healthy subjects.

This

Antibodies to C5

substantially inhibited this chemotactic activity.

In addition,

these gingival extracts induced chemotactic activity from fresh

serum. Complement-related compounds may, therefore, be important
in the chemotaxis of mononuclear cells in periodontal disease and
in the change of predominant cell type that occurs.

The above studies do not address the mechanism or the location of the complement conversion in the periodontal diseases.,

but many of the initiating factors of both the classical and the

alternative pathways are present in the periodontium.

Bacteria

and their products, immunoglobulins, and complement components

are all located in the area of the periodontal pocket, supporting
the concept of a potential role for complement in periodontal

disease.
Although immune complexes have not been identified in
tissues taken from either dogs or humans with chronic periodontitis (Clagett and Page 1978), other evidence suggests a role
for the classical pathway of complement activation in periodontal
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disease following the interaction of antigens and antibodies.

Immunoglobulins

were first described in gingival fluid by

Brandtzaeg (1965).

Several laboratories since have identified

predominantly IgG,

but also IgA without a secretory piece

(Holmberg and Killander 1971),

and IgM in gingival

fluid

(Shillitoe and Lehner 1972, $chenkein and Genco 1977a).

Anti-

bodies also have been demonstrated in the serum of individuals

with periodontal disease that are reactive with many species of

periodontopathic bacteria, including Actinomyces. Actinobacillus,

Bacteroides,_ Fusobacteria and Leptotrichia (Mergenhagen et al.

1965, Genco et al. 1974, Evans et al. 1966, Mansheim etal.
1980).

In juvenile periodontitis patients, high serum and gingi-

val fluid antibody titers to Actinobacillus actinomvcetemcomitans

have been observed.

Additionally, local synthesis within the

gingival tissues of antibodies and complement have been reported

(Schlossberg 1971, Payne 1975).

Gingival plasma cells have been

shown to synthesize immunoglobulins specific for oral bacterial
antigens.

Berglund (1971) demonstrated antibody activity in

extracts of inflamed gingival tissue.

Results have been conflic-

ting in determining the type of immunoglobulins produced within
the periodontium; Brandtzaeg (1965) noted primarily IgG pro-

duction, Platt et al. (1970)
IgGI,

IgG3, IgG 4.

IgM, and Mackler et al. (1978):

Lally and coworkers (1980), using

14C-labelled

amino acids with immunoelectrophoresis and autoradiography,

de-

tected IgG and IgA synthesis locally in chronically inflamed

gingival tissues.

They observed no immunoglobulin synthesis in
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healthy gingival tissue.

Using a similar method, Lally et ai.

(1982) demonstrated local biosynthesis of C3 and C5 in the majority of individuals with chronically inflamed gingiva, but not in

healthy tissue.

Immunofluorescent studies have been reported

which describe IgG, IgM, and C3 within the gingival tissues of

gingivitis (Toto et al. 1978a) and periodontitis (Toto et al.
197 8b).
Investigators have used immunofluorescent techniques to

_

determine the presence of immunoglobulins and complement bound to

subgingival bacteria.

Only a fraction of the total bacteria in

each smear were positive for the immunoglobulins or complement

(Platt et al. 1970, Genco et al. 1974).

Nisengard and Jarrett

(1976), however, reported that all bacterial samples obtained
from periodontitis and most from gingivitis revealed

vivo

coating of some bacteria with IgG, IgA, IgM, IgE, and/or comple-

ment.

Recently, bacteria coated with Clq and C4 have been demon-

strated in dental plaque from chronic periodontitis pockets,

visualized by light and electron microscopy with specific antibodies to human Clq and C4 and reacted with peroxidase-antiper-

_
_
_

oxidase (Chisikovsky et al. 1982).

Many constituents of dental

plaque have been shown to consume complement by the alternative

activating pathway or the classical pathway, or both.

Okuda and

Takazoe (1980) observed complement cleavage in all sera following

exposure to dental plaque.

oralis,_po!ysaccharide from

viscosus,

m_elaninogenicus,

mutans, S. sanguis, F_ nucleatum

cell wall and other oral bacteria cause complement activation
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(Ni!sson et al. 1975, Allison et al. 1976, Shivers et al. 1974,

Hawley and Falker 1977).

The incubation of dental plaque and

serum results in the production of a factor which causes histamine release from basophils.

This factor is inhibited by anti-

body to C5 and it is thought to be C5a (Olsson-Wennstrom et al.
1978).

This abundance of oral bacteria,

Gram-negative,

both Gram-positive and

capable of activating complement through the

alternative pathway, and the presence of specific antibodies

strongly suggests that many of the inflammatory events associated
with periodontal inflammation are complement-related.
Studies in decomplemented animals provide further support, to

the importance of complement in periodontal disease.

Dogs,

immunized with plaque extract and decomplemented with carragheenan (prevents complement activation by blocking the reaction

between Cl and the immune complexes (Borsos et al. 1965, Ward and
Cochrane 1965) showed markedly diminished PMN migration and vascular exudation when challenged with plaque extract (Kahnberg et

al. 1977).

However, when Cobra Venom Factor (a C3b analog and

alternative pathway activator) decomplemented dogs which had not
been previously immunized were challenged with dental plaque,

only a minor change was observed in the number of leukocytes in
the challenged junctional epithelium (Kahnberg et al. 1976).

The

vascular response to the applied plaque extract was decreased in
these decomplemented dogs, however.

Wennstrom and coworkers

(1980) applied extracts from pure cultures of _Actinomyces viscosus and Cap_nocytophaga ochracea to the gingival margin of Cobra
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Venom Factor decomplemented dogs and observed a markedly diminished leukocyte accumulation in the junctional epithelium,

sug-

gesting that complement plays an in vivo role in leukocyte chemotaxis and gingival inflammation.

Other consequences of complement activation correspond with

events in periodontal disease.

Complement cleavage generates

mediators of vascular and cellular inflammatory phenomena through

chemotaxis, anaphylatoxin production and host and bacterial cytotoxicity.

In addition,

the opsonizing effect of C3b,

important

in host defense in the gingival sulcus, contributes to tissue

damage by release of histolytic enzymes by phagocytizing cells.
C3b also induces the release of lymphokines from lymphocytes, and

has been implicated in stimulating the release of hydrolytic

enzymes from macrophages (including collagenase and elastase),
resulting ultimately in connective tissue destruction, a hallmark
of periodontal disease.

Complement has also been linked to bone

resorption, an important phenomenon in periodontitis.

Fetal rat

bone resorption was observed when bone cultures were incubated in

fresh rabbit serum.

The resorption did not occur when the bones

were cultured in heated rabbit serum or C6-deficient serum but
recurred when purified C6 was added (Raisz et al. 1974).

The

mechanism of complement cleavage in gingival fluid in periodontal

disease is unknown, but it is clear that C3 is degraded to its
final products.

This can be achieved by i) activation of the

classical pathway, 2) initiation of the alternative activating

pathway, or 3) non-complement proteolytic cleavage of complement
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components.

The presence of constant antigenic challenge in the

periodontal pocket, plaque-specific serum antibodies and the

observation that plasma cells are found in tissues adjacent to

the pocket,

suggest the potential for antigen-antibody reactions

with consequent classical pathway complement activation.

Experi-

mentally, Arthus reactions induced in the gingiva of immunized

monkeys resulted in an inflammatory infiltrate and osteoclastic
resorption similar to that found in periodontitis (Nisengard et

al. 1977).

IgG and C4 deposits were observed in perivascular

areas in these animals.

It is therefore possible that specific

antibodies which reach the periodontal tissues via serum and

locally synthesized immunoglobulins with specificity for bacterial antigens may interact with bacteria and their products to

initiate classical pathway activation.
The diseased gingival tissues contain endotoxin and other

bacterial products capable of fluid-phase alternative pathway

activation.

In addition, cleavage of complement components by

non-complement proteolytic enzymes may also occur.

It is clear that the activation of complement plays an
important role in the mediation of inflammation in many chronic

inflammatory diseases.

Conversion products of C3, C4, and B have

been reported to be present in gingival fluid from severe periodontitis lesions.

Because of the limited amounts of gingival

fluid available from lesions of minimal inflammation, no longitu-

dinal studies of complement activation in periodontal disease

have been reported.

Using an assay developed by the Master’s

candidate, sufficient sensitivity is now available to assess
longitudinal changes in complement conversion in periodontal

disease.

Therefore, the purpose of this study was to determine

the extent of conversion of complement components of both the

classical and alternative pathways in human gingival fluidobtained from lesions of chronic periodontitis, prior and subse-

quent to initial periodontal treatment.

The differences in the

measured extent of conversion of the complement components C3,
C4, and B from the same site were statistically compared before
and after therapy.

The information gained may provide a better

understanding of the role of complement activation in the initiation and progression of periodontal disease.
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SPECIFIC OBo-EC

The specific objectives of this study were to:

i)

develop a sensitive method to simultaneously assay C3, C4,
and B conversion from a single gingival fluid sample

2)

nieasure the extent of conversion of C3 in gingival fluid
from patients with chronic periodontitis

3)

measure the extent of conversion of C4 in gingival fluid
from patients with chronic periodontitis

4)

measure the extent of conversion of B in gingival fluid from
patients with chronic periodontitis

5)

determine the differences in the measured extent of conversion of C3, C4, and B in gingival fluid from the same perio-

dontal sites after initial periodontal therapy.

34

MATERIALS and METHODS

Se!e.ction o_f_subjects

Participants were selected from pa-

tients presenting for treatment at the out-patient clinics of the

University of Connecticut School of Dental Medicine.

The nature

and risks of the study were explained to all participants and

informed consent was obtained.

Subjects received a complete oral

examination including Gingival Index (L6e and Silness 1963),

Plaque Index (Silness and Le 1964), measurement of pocket depth
and loss of periodontal attachment in millimeters, presence of

suppuration and bleeding on probing (recorded as 1 if present, 0

if absent).

These indices were recorded at a visit prior to the

initial sampling, and confirmed immediately subsequent to sampl ing.

Subjects chosen for study had clinical and radiographic

evidence of 20 to 50% bone loss on many teeth.

The severity of

periodontal disease in this group was consistent with that which

would be expected due to age and local factors.

Subjects ranged

in age from 40 to 60 years, and had a mean Plaque Index greater

than I, with pocket depths of 4-9 mm, and loss of attachment

ranging from 1-9 mm.
Gingival fluid from nine individuals with chronic periodontitis was obtained at selected times before and after treatment

from representative sites.

In some patients, samples were taken

twice prior to treatment (baseline).

The subjects were then

instructed in oral hygiene (brushing and flossing) and received
thorough mechanical debridement (root planing and scaling). Sites
35
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were sampled again at 2-4 weeks after therapy.
indices were repeated after each sampling.

sampled twice (2 and 4 weeks) after therapy.

All clinical

Some sites were
Blood samples were

also taken at the initial visit and serum separated.

Collection o_ gingival fluid:

The sites selected for study

were interproximal areas which best reflected the disease status
of the patient.

Electronics,

Standardized filter paper strips (PER-601, Harco

Winnipeg, Manitoba), wetted with 0.01M

Na2EDTA

and

completely dried before use to prevent C4 conversion upon electrophoresis (Sjoholm and Laurell 1973), were inserted a premarked length (3 mm) into the pocket and allowed to remain undisturbed for 3 min.

Prior to fluid collection,

the tooth was

gently washed with water, dried with air and isolated with cotton

rolls.

Samples contaminated with blood or plaque were discarded.

The samples were then placed in individual plastic containers

coded by a person other than the investigator and subjected to

crossed-immunoelectrophoresis within 1 hr.
Antisera:

Solid-phase absorbed antisera specific for C3

(beta-l-C, beta-l-A), C4, transferrin, and B, respectively, were
obtained from Atlantic Antibodies (Scarborough, Maine) and tested
for specificity by immunoelectrophoresis vs. human serum.

Fresh

serum and zymosan-activated serum served as negative and positive

controls, respectively, for C3 conversion to C3c and B conversion
to Bb.

EDTA-anticoagulated plasma and immune-complex treated

serum (Sjoholm and Laurell 1973) were used as negative and positive controls,

respectively, for C4 conversion to C4c.
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o_f ComplemenZ Components

Gingiv_a! F_:

Comple-

ment conversion was assessed by crossed immunoelectrophoresis.
The coded filter paper strips were removed from their containers,

trimmed to 5 mm in length, positioned over a 1.6 mm hole cut in

agarose,

and folded into the hole with a sharp instrument

(Patters et al. 1979).

Fluid components migrated out of the

strip into the agarose when electrophoresis was begun.

First dimension electrophoresis was carried out in 1.0%

agarose (SeaKem) in barbital buffer (pH 8.6, ionic strength=0.02)
containing 0.01M

Na2EDT;U

An 8 volts/cm current was applied to

the 1.5 mm thick gel containing the filter paper strips for 90
min at

15C.

Second dimension electrophoresis was carried out using a

technique developed by the Master’s candidate, in which the
conversion of C3, C4, and B could be simultaneously assayed from

a single gingival fluid sample.

The first dimension gel was cut

with a razor blade into a 1 cm slab containing the filter strip
and its migrated components and transferred to a 50x50xl mm glass

plate.

Agarose (3.1 ml) containing a predetermined optimal con-

centration of specific antisera to B and to C3 was poured onto

the remaining 4 cm of the plate.

After this gel had solidified,

2.0 cm of this agarose was rtemoved, leaving the 1 cm wide first
dimension gel and 2.0 cm of anti-B and anti-C3.

Finally, 1.5 ml

of agarose containing specific antisera to C4 and to human transferrin (reference protein) was poured onto the remaining part of
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the plate.

In this manner, a 50x50xl mm gel had been formed con-

taining the first dimension gel, a 2.0 cm wide slab of agarose
with anti-B and anti-C3, and a 2.0 cm wide gel containing anti-C4
and anti-transferrin.

The solidified gel was placed on the electrophoresis appar-

atus at 90

to the direction of the first dimension with the

first dimension gel toward the cathode.

The gel was connected

with the buffer by means of filter paper wicks.

(2volts/cm) was then applied at 15C for 16 hours.
rinsed with distilled water, dried at

60C.,

Current

The gels were

and stained with

Coommassie Brilliant Blue R-250, and the precipitates measured as
described below.

The areas under the curve formed by each precipitate were
estimated on a 7X magnified projection by measuring the rocket

height and multiplying by the rocket width measured at one-half
the rocket height (Weeke 1973).

The percentage of C3 converted

to C3c was then determined by the following formula:
%C3 conversion

Area.. of the C3C. rocket
x i00
Area of C3c rocket + Area of C3 rocket

Conversion of C4 to C4c was assessed by appearance of a less

anodally migrating rocket when compared with C4 in EDTA-containing serum.

Transferrin, which produced a single rocket which

migrated reproducibly between the C4 and C4c rockets, served as a
marker to aid in the identification of a single rocket as either

-39C4 or C4c (Scharfstein et al. 1978).

The percentage of C4 con-

version was calculated as described for C3c/C3.

Because of the

heterogeneity of human C4, serum samples were used as controls to
indicate the migration pattern of C4 for that individual.

B produced a single rocket which migrated anodally, while

Bb, under the conditions of pH and buffer strength used, produced
a rocket with minimal gamma mobility.

Since the Bb rocket was

always small, quantitative measurements were not possible.
Codes were broken after the gels were analyzed.

Statistical analys_es.

Statistical significance of longi-

tudinal changes in clinical indices and complement conversion

following therapy was assessed by both parametric and non-parametric methods.

Interval data (pocket depth, loss of attachment,

area of precipitates formed by complement components, and percen-

tage conversion) were analyzed using the correlated (paired) t-

test.

Using this test, t is determined by dividing the mean of

the differences between pairs by the standard error of the mean

difference.

The probability value, p, is found from t at the

degrees of freedom equal to the number of pairs minus one.

Non-

interval data (plaque index, gingival index, bleeding on probing,
and suppuration) were analyzed using the Wilcoxon matched-pairs

signed rank test.

.are

In this test, the differences between pairs

ranked and the smaller of the sums of the positive or nega-

tive ranks is T.

Although

means

and standard deviations are

presented for descriptive purposes, they were not used in the
statistical analyses of non-interval data.

Method:

To establish the crossed-immunoelectrophoresis

method introduced in this study, fresh serum was used as the
negative control.

Zymosan-activated serum served as the positive

control for C3 and B conversion and immune-complex activated

serum was utilized as the positive control for C4 conversion.
The concentrations of antisera in the gels were adjusted to

achieve C3, C4, and transferrin rockets with an area of approxi-

mately i000 units on the 7X projection when 0.5 ul of serum was

used.

The optimal concentrations for these antisera were 2.0

ul/ml agarose for anti-C4, 1.4 ul/ml agarose for anti-C3, and i0
ul/ml agarose for anti-transferrin.

Due to the low

concentration

of B in serum, rockets of this magnitude were never possible.

Therefore, the Anti-B antiserum was adjusted to a concentration
of 4.0 ul/ml agarose, which produced a rocket of about 250 units

on the 7X projection from 0.5 ul of serum.

Bb appeared only as a

flat unmeasurable precipitate, and thus was recorded only as

present or not present.

Throughout the course of this study, a

single lot of each antiserum was used.
Precipitates formed by multi-dimension crossed-immunoelectrophoresis were compared with those from standard crossed-

immunoelectrophoresis using a single antiserum.
of all proteins examined-

The precipitates

C3, C3c, C4, C4c, B, Bb and transfer-

rin were of similar area and mobility when compared to the multi-

layer gels.

Therefore, the multi-dimension technique did not

cause significant distortion of the precipitates.
40
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Reproducibilty

o_

Method-_.

To establish the reproducibility

of the method, 26 sites were examined twice prior to treatment.

Additionally, 16 sites were sampled two times post-treatment.

Analysis of the two pretreatment sample plaque index values by
Wilcoxon (for non-interval data) revealed a significant variation

between Time 1 and Time 2 (p<=0.005, Table i).

During this time,

the plaque index declined from a mean of 1.88 (Time I) to 1.35

(Time 2).

Comparis.on of the two post-treatment plaque index

values showed no significant difference between Time 3

(mean=0.63) and Time 4 (mean=0.75).
Wilcoxon analysis of the two pretreatment gingival index
values (Table 2) disclosed no significant variation between Time

1 (mean GI=1.54) and Time 2 (mean GI=1.35).

Also, no significant

difference existed between the post-treatment values, (Time 3

mean GI=I.12)

and Time 4 (mean GI=1.25).

The two pretreatment values for bleeding on probing (Time 1

mean bleeding on probing=0.81, Time 2=0.73) were not significant-

ly different (Table 3).

Comparison of the two post-treatment

mean bleeding on probing values showed no significant variation

(Time 3=0.50 Time 4=0.63).

Analysis of the two pretreatment and

the two post-treatment suppuration values by Wilcoxon revealed no

significant changes in either comparison (Table 4).

The correlated t-test was used for analysis of the interval

data.

Table 5 contains the values for the reproducibility of

pocket depth measurements.

No significant change in pocket depth

occurred between the two pretreatment values (Time 1 mean pocket
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depth=6.38 mm and Time 2 mean pocket depth=6.46 mm).

However, a

slight but significant difference was apparent between the two

post-treatment readings (p=0.015).

The Time 3 mean pocket depth

was 5.81 mm and the Time 4 mean pocket depth was 5.31 mm.
Loss of attachment reproducibility analysis followed a simifar pattern (Table 6).

Using the correlated t-test, no signifi-

cant variation was found between the two pretreatment values
(Time I mean loss of attachment=5.38 mm and Time 2 mean loss of

attachment=5.19 mm).

There was a small but significant differ-

ence between the two post-treatment measurements (p<0.0034).
The Time 3 mean loss of attachment was 6.00 mm and the Time 4
mean loss of attachment equalled 5.38 mm.

Table 7 contains the reproducibility analysis of the per-

centage C3 conversion by correlated t-test.

The mean percentage

of C3 conversion was 78.2% and 62.2% for Time 1 and Time 2,

respectively.

No significant differences were apparent between

the two pretreatment or between the two sets of post-treatment

percentage C3 conversion values (Time 3=51.4% and Time 4=39.4%).

Therefore, for all pretreatment parameters measured on two
occasions only the plaque index differed significantly.

In com-

paring the two sets of post-treatment values, a slight but significant decrease in both pocket depth and loss of attachment
occurred between Time 3 and Time 4.

All other variables examined

did not significantly differ.

Clinical Lo_ngitudinal Results-

For analysis of the changes

in the clinical variables over the course of treatment,

37
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chronic periodontitis sites were examined.

compared with Time 4 values.

Time 1 values were

Wilcoxon analysis was employed for

non-interval data and correlated t-test for interval data.

Comparison of plaque index values (Table 8)

revealed a

significant decrease (p<=0.005) following periodontal treatment.
The pretreatment plaque index mean was 1.76 and the post-treat-

ment plaque index mean equalled 0.95.

The Gingival Index fol-

lowed a parallel pattern (Table 9), and declined significantly
(p<=0.005) between pretreatment and post-treatment measurements.
The mean pretreatment GI was 1.54 and the mean post-treatment GI

was I.ii.

Bleeding on probing (Table I0) also showed a signifi-

cant decrease after periodontal treatment (p<=0.005), decreasing
from a pretreatment mean of 0.86 to a post-treatment mean of

0.41.

Suppuration values

(Table Ii)

(p<=0.025) over the course of treatment.

declined significantly
The mean pretreatment

suppuration value was 0.22, but the post-treatment mean was 0.05.

From the correlated t-test analysis of pocket depth measure-

ments (Table 12), it was apparent that a highly significant
decrease (p<=0.00005) occurred between the pretreatment measurements (mean pocket depth=6.32 mm) and the post-treatment values

(mean pocket depth=5.05 mm).
(Table

13)

was

also

A reduction in loss of attachment

highly statistically significant

(p<=0.00005), changing from a pretreatment mean of 5.65 mm to a

post-treatment mean of 4.84 mm.
ople_men___t and Transferrin LoDgitudi.na! Res..ults:

For

analyses of the changes in complement cleavage during periodontal
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Therefore, several significant changes in complement cornponents occurred following periodontal treatment.

The area of

the C3 precipitate increased; the area of the C3c precipitate

decreased, and the percentage of C3 conversion declined sharply.
C4, C4c, B, Bb and transferrin did not show any statistically
significant change.
Figure 1 is a photograph of a gel from a gingival fluid

sample taken prior to periodontal treatment.

Precipitates rep-

resenting transferrin (T), C4, C3, C3c, B, and Bb are visible.
Approximately 60% of the available C3 has been converted to C3c.
Figure 2 is a photograph of a gel obtained after crossed-immuno-

electrophoresis of gingival fluid taken from the same site as in
Figure I, but sampled following periodontal therapy.

Again pre-

cipitates representing transferrin (T), C4, C3, C3c, B and Bb can
be observed.

The C3c rocket is diminished in area relative to

the C3 rocket in this post-treatment sample and represents 27% C3

conversion.

DISCUSSION

The Method.

The sampling and crossed immunoelectrophoresis

technique introduced in this paper was highly sensitive and

allowed the assessment of the complement components from a single
gingival fluid sample obtained from a specific site.

No pooling

of samples was necessary as the proteins could be measured in

gingival fluid samples as small as 0.2ul.

Since no elution of

the samples was required, the dilution of C3 beyond detectable

levels as occurred in the report of Attstrom et al. (1975) was
also avoided.

The sensitivity of the new procedure and the

sampling method, therefore, allowed the analysis of complement

components in areas of minimal periodontal inflammation, making
possible a longitudinal study of complement activation in chronic

periodontitis over the course of treatment.

No previous longitu-

dinal studies of complement activation in gingival fluid have
been reported.

Additionally, it was possible to ascertain not

only whether the complement terminal pathway was activated by the

presence of C3 conversion products, but also which initiation
pathway might be utilized.

If C4 cleavage products are present,

then the classical pathway is likely activated.

If B cleavage

products can be observed, alternative pathway initiation is suggested.
Reproducibility of th9 method.

The major objective of this

study was to determine longitudinal changes in complement cleavage in gingival fluid that occurred with treatment of the periodontal lesions.

Prior to making these observations, it was
46
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necessary to determine the stability of the clinical and complement measures.

Therefore, a subset of periodontal lesions was

assessed clinically and for complement cleavage on two occasions
prior to and two occasions after therapy.

A comprehensive clini-

cal examination was performed at both pretreatment and both post-

treatment visits and included the plaque index (Silness and Le
1964), gingival index (Le and Silness 1963), bleeding on probing, suppuration, pocket depth and loss of attachment in milli-

meters, all recorded after the gingival fluid samples were taken.
In comparing Time 1 with Time 2 samples (Table I), only the
plaque index decreased significantly (p<=.005).

This improvement

in the plaque index can be attributed to the fact that the patient had started a series of periodontal treatment visits and
had received some hygiene instruction.

All other clinical para-

meters and complement component measurements were not statistically different between Time I and Time 2 (Tables 1-7).

In addi-

tion, reproducibility of complement component measures between
the two pretreatment samples was excellent.

Therefore, Time 1

values were selected for further statistical comparisons.

Identical periodontal sites were also examined and sampled

at two and four weeks post-treatment.

Comparison of the two

posttreatment samples revealed a small decrease in pocket depth
(0.5mm) and loss of attachment (0.6mm) with the longer healing
time (Table 5 and 6).

This decrease in loss of attachment may be

caused by a decrease in inflammation of the periodontal tissues
with a consequent tighter adaptation of the tissue to the tooth
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and a greater resistance to periodontal probing.

All other

clinical parameters and complement measurements did not vary

significantly between the two post-treatment samples.

Results

from these experiments indicated that both clinical and comple-

ment parameters appeared reproducible before and after therapy.

Therefore, changes in these measurements after therapy likely
resulted from treatment rather than random fluctuations.

For

analysis of the changes occurring longitudinally with treatment,
the first pretreatment sample (Time i) was compared with the last

post-treatment sample (Time 4).
Complement 9.1eavage in per iodontitis.

It is clear from the

results of this study that C3 is cleaved to C3c in the gingival

fluid of chronic, untreated periodontal lesions.

This observa-

tion is supported by the cross-sectional findings of Attstrom et

al.

(1975),

(1979).

Schenkein and Genco (1977a),

and Patters et al.

The cleavage of C3 may be caused by three primary mech-

anisms: classical pathway, alternative activating pathway, or

proteolysis due to enzymes present in the periodontal pocket.
With the continual presence of antigenic challenge and the
observation of IgG antibodies reactive with oral bacterial anti-

gens in the gingival fluid, it is feasible that a local antigenantibody interaction is possible with consequent classical cornplement pathway activation.

However, few immune complexes have

been observed in the periodontal tissues of chronic periodontitis
(Clagett and Page 1978, Platt et al. 1970, Genco et al. 1974).

In all 37 chronic periodontitis sites examined,

C4 cleavage
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products were not observed in the gingival fluid.

It therefore,

seems unlikely that .complement activation occurred primarily by
this pathway.

There is evidence that soluble bacterial products capable of
fluid-phase alternative pathway activation (such as endotoxins)

can enter the periodontal tissue through the damaged crevicular
epithelium (Schwartz et al. 1972)..

Many agents are capable of

activating the alternative activating pathway of complement, and
several of these are present both in the periodontal pocket and
the surrounding tissue.

T-independent antigens and B-cell mito-

gens can activate this pathway.

In addition, several bacteria

have been shown to initiate this alternative cascade,

gram-negative organisms, Actinomyces
ide from StreD.tococcus mutans.

yscosus

including

and a polysacchar-

Microorganisms are certainly

present in the periodontal pocket and have been observed in the
tissue of severe periodontitis and juvenile periodontitis (Sagli

1982, Frank 1980).

Gram negative organisms, including Fusobac,

terium nu_cleatum and Bactero.ides gingivalis found in chronic

periodontitis have been shown to be capable of initiating the
alternative activating pathway (Nilsson et al. 1975, Allison et

al. 1976, Shivers et al. 1974, Hawley and Falker 1977). This
evidence, coupled with the fact that B and its cleavage product
Bb were consistently present in untreated periodontitis, while C4
cleavage products were not, suggests that in the periodontal

pocket, nonspecific direct activation of C3 may occur via the
alternative activating pathway.
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Pro.teoly_tic _Enzymes.

C3 and C5 have been split //!

by

complement-unrelated enzymes, such as purified neutral proteases
from PMNs (Johnson et al. 1976,. Bronzna et al. 1977, Taylor et

al. 1977).

In

he above

studies, it was observed that elastase,

collagenase and cathepsin G were

capable of splitting C3 and C5

into smaller fragments electrophoretically similar to C3a and

These and similar enzymes may be present in the periodontal

C5a.

pocket and the possibility does exist that complement cleavage in

periodontal disease occurs by this means.

No attempt was made in

the current study to evaluate the contributions of complement-

unrelated enzymes in complement cleavage in the gingival fluid.
Longitudinal changes

.f.ollowng peri_odontal therapy.

Over

the treatment period, plaque index, gingival index, bleeding on

probing, suppuration, pocket depth, and loss of attachment all
decreased significantly (Tables 8-13).

These substantial changes

in the clinical parameters demonstrated the effectivenessof the
initial periodontal therapy.

Measurements of transferrin showed

no variation between the pretreatment and post-treatment samples
(Table 19).

Transfer r in,

a protein unrelated to changes in

inflammation, served as a marker and, therefore, should not have
changed with periodontal treatment.

Other factors which might

affect the results were minimized as follows: C4 conversion due

to electrophoresis was suppressed by the treatment of the filter

paper strips used for sampling with
1973).

Na2EDTA

(Sjoholm and Laurell

Samples were processed within one hour to minimize

vitro exposure of the gingival fluid to bacterial plaque on the
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filter strip.

Patters et al. (1979) demonstrated that plaque

present on the sampling str.ip did not activate the complement

present in fluid absorbed into EDTA-containing filter paper.

In

addition, serum samples from individuals in the study were handled in an identical manner to gingival fluid. No C3, B, or C4

cleavage products were observed in the serum tested and they,

therefore, served as the negative controls.

This was especially

critical in the evaluation of C4 which is heterogeneous in humans

and thus has slightly variable mobilities.

The transferrin mar-

ker also served to reproducibly distinguish C4 from C4c mobility

(Scharfstein et al. 1978).

Immune complex-activated serum served

as the positive control to visualize C4c mobility.

Additionally,

clinical measurements and filter strip samples were taken by the

Master’s candidate to eliminate inter-operator inconsistency.
All samples were coded by a person other than the Master’s candi-

date and these codes were not broken until the gels had been

measured.

The evidence of clinically successful therapy, the

stability of the reference protein, transferrin, and the above
precautions and controls suggested that any changes in C3, C4 or

B would be the result of therapy rather than random changes.
For all paired samples (pretreatment vs. post-treatment),

however, C3 levels increased (Table 14) and C3c amounts decreased

(Table 15) significantly.

Therefore, the percent of C3 conver-

sion also decreased significantly (Table 16, p<0.00005), de-

creasing from 70.0% to 37.5% overall.

Less complement cleavage

was therefore present in the gingival fluid after initial therapy
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than in the untreated chronic periodontitis lesions.

B (Table

18) and Bb levels did not-change significantly between pretreat-

ment and post-treatment levels,
decreased Bb after treatment.

but a trend did exist for

This could not be statistically

confirmed due to the difficulty of quantitation of Bb.

C4 con-

version products were never observed in the pretreatment samples,
and it remained uncleaved throughout treatment.

Native C4 levels

did not statistically change with treatment (Table 17).

This demonstration of a reduction in the C3/C3c ratio fol-

lowing initial periodontal therapy suggests a correlation between
conversion of C3 in gingival fluid and the state of periodontal

health.

The observation of complement cleavage products in gin-

gival fluid from diseased sites and an understanding of their
biological implications makes complement-mediated tissue injury a
distinct possibility in periodontal disease.

This is underscored

by the fact that the conversion products decrease with a

concom-

mitant decline in clinical signs of disease.

Protective and destructive aspects of complement activation.
The activation of complement may play a protective role in the

periodontal tissues.

The opsonization of bacteria and their

products, chemotaxis, bacterial cell cytotoxicity, and modulation
of cell-mediated immunity are all first-line defense mechanisms

involving complement.

Since the periodontal tissues are con-

stantly challenged by pathogenic bacteria and their toxic pro-

ducts, greater tissue damage than is observed might be expected
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Chronic periodontitis, however, is a slowly progres-

to occur.

sive pathologic process.

Complement likely figures prominently

in this protectiwe function both through enhanced phagocytosis
and bacteriolysis.

However, activation of the complement cascade induces many
phenomena associated with inflammation and concommitant tissue

damage.

This is accomplished in many ways, primarily through the

release of limited proteolytic cleavage products formed by the

complement cascade.

The results of this study indicate that the

percentage of C3 cleaved to C3c correlate with clinical measures
of inflammation suggesting an ongoing pathologic process.

The

balance between host protection and tissue damage remains to be

determined.
Complement

_other _chronic _inflammatory .diseases.

Chronic

periodontitis and rheumatoid arthritis are similar in several

ways.

They--both involve the development of inflammatory disease

within a specific extravascular site.

The majority of inflamma-

tory cells present locally in both disease entities are mononuclear cells.

Despite the fact that the involved tissues in both

cases have been shown to contain cells which synthesize many
complement components, complement components in both gingival
fluid (Schenkein and Genco 1977a) and synovial fluid (Pekin and

Zvaifler 1964, Hunder et al. 1977) are at reduced levels.

This

suggests that complement may be utilized in both of these disease

processes.

In fact, C3 cleavage products are found in both
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synovial fluid (Perrin et al. 1977) and gingival fluid (Attstrom

et al. 1975, Schenkein and Genco 1977b, Schenkein et al. 1976)
from diseased si.tes.

However,

t

is suggested from this study that the mechanism

of complement utilization may differ between the two disease

entities.

Immune complexes are commonly found in RA patients

(Winchester et al. 1970, Townes and Marcus 1972) and are thought

to initiate the complement cascade and contribute to the progression of the disease.

However, immune complexes have not been

regularly observed in chronic periodontitis.

Results of this

study indicate that in chronic periodontitis, complement cleavage

occurs primarily via the alternative activating pathway or by
non-complement enzymes.

No C4 cleavage (a classical_ pathway

component) was observed in the gingival fluid of these patients.

In RA synovial fluid, C4 is the most consistently depressed
complement component (Perrin et al. 1973) and complement cleavage

is believed to occur primarily through the classical pathway with
the alternative activating pathway in an amplifying role (Kaplan

et al. 1980).

It is apparent, therefore, that chronic periodon-

titis is not principally an immune-complex disease, like RA or

SLE, and that complement cleavage does not seem to occur by the
classical pathway.

A multitude of factors which initiate the

alternative activating pathway, including bacteria and their

products, arepresent in the periodontal pocket and may explain
the cleavage of complement.

The following conclusions can be made from the studies

preaent:ed in this. thesis
The

technique

introduced in thi paper wa suitable for the

assessment of complement components C3, C4, and B and their
conversion products.

The method was adequately quantitative

for the complement components studied with the exception of

2)

C3 is converted to the cleavage product C3c in the gingival
fluid of chronic periodontitis lesions.

3)

C4 cleavage products were never identified in thegingival
fluid of chronic periodontitis lesions.

4)

B cleavage product, Bb, was present consistently in the
gingival fluid of chronic periodontitis lesions.

5)

The percentage of C3 converted to C3c in gingival fluid from
chronic periodontitis lesions decreased significantly fol-

lowing periodontal therapy.

This change paralleled the

decline in clinical measurements of inflammatory disease.
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The development of the

new_

sampling method and crossed

immunoelectrophor.esis..technique introduces the possibility for
numerous additional studies.

The longitudinal evaluation of

complement changes during treatment should be continued through-

out the surgical phase of treatment.

In addition, complement

cleavage in the gingival fluid of patients in the maintenance

phase of periodontal care could be monitored periodically and the
complement changes examined for correlation with clinical meaSurements and disease recurrence.

Complement cleavage may occur

prior to changes in measurable clinical parameters and, thus,
complement cleavage measurements _could be the first sign of

recurring inflammation.
Other periodontal diseases such as juvenile periodontitis
and rapidly progressive periodontitis could be thoroughly ex-

amined both cross-sectionally and longitudinally to evaluate the
mechanism of complement initiation-and complement changes with

treatment.

In a preliminary retx)rt, evidence for C4 cleavage in

juvenile periodontitis was presented by Schenkein and coworkers
(1976), but further studies are indicated.

In addition, the

technique presented here is ideally suited for longitudinal analysis of complement cleavage in experimentally induced gingivitis

because-the small amounts of gingival fluid available from

healthy sites can be analyzed.
To provide further information as to the mechanism of com-

plement cleavage in periodontal disease, the role of complement56
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unrelated proteolytic enzymes could be explored.

Radio-labelled

C3 would be incubated with gingival fluid in the presence of an
inhibitor of the complement system such as EDTA or heat inactiva-

tion, electrophoresis conducted, and the amount of labelled C3
converted could be evaluated by autoradiography to establish the

presence of proteolytic enzymes in gingival fluid.

CITtTIOS
Allison, A.C., Schorlemmer, .H.U. and Bitter-Suermann, D. 1976.
Activation of complement by the alternative pathway as a factor
in the pathogenesis of. periodontal disease. Lancet 2:1001-1003.

Laurel,

A.B., Larsson, U. and Sjoholm, A. 1975.
Complement factors in gingival crevice material from healthy and
inflamed gingiva in humans. Journal of Periodontal Research
10:19-27.

Attstrom, R.,

Augener, W., Grey, H.M., Cooper, N.R. and Mller-Eberhard, H.J.
1971. The reaction of monomeric and aggregated immunoglobulins
with CI. Immunochemistry 8:1011’1020.
Becket, E.L., Showell, H.J., Henson, P.M., and Hsu, L.S. 1974.
The ability of chemotactic factors to induce lysosomal enzyme
release. I. The characteristics of the release, the importance
of surfaces and the relation of enzyme release to chemotactic
responsiveness. Journal of Immunology I12:2047-2054.

Berglund, S.F. 1971. Immunoglobulins in human gingiva with
Journal of Periodontology
specificity for oral bacteria.
42: 546-551.
Bianco, C., Eden, A. and Cohn, Z.A. 1976. The induction of
macrophage spreading: role of coagulation factors and the complement system. Journal of Experimental Medicine 144:1531-1544.
Bokish, V.A. and Mller-Eberhard, H.J. 1970. Anaphylatoxin
inactivator of human plasma: its isolation and characterization
as a carboxypeptidase. Journal of Clinical Investigation
49:2427-2436.

Borsos, T., Rapp, H.S. and Crisler, C. 1965. The interaction
between carragheenan and the first component of complement.
Journal of Immunology 94: 662-666.
Brandtzaeg, P. 1965. Immunochemical comparison of proteins in
human gingival pocket fluid, serum and saliva. Archives of Oral
Biology 10:795-803.
Brill, N. and Bronnestrom, P 1960. Immunoelectrophoretic study
of tissue fluid from gingival pockets. Acta Odontologica Scandinavia 18:95-100.

Brinch, L., Vinje, O., Teisberg, P., Mellbye, O.J. and Aakesson,
I. 1982. The i__n yivometabolism of C3 in ankylosing spondyltis.
Annals of the Rheumatic Diseases 41:86-89.

58

-59-

Britton, M.C. and Schus, P.H. 1971. The complement system in
rheumatoid synoviti s. II. Intracytoplasmic inclusions of immunoglobulins and complement. Arthritis and Rheumatism 14:87-95.

Brozna, J.P., Senior, R.M., Kreutzer, D.L. and Ward, P.A. 1977.
Chemotactic factor inactivators of human granulocytes. Journal
of Clinical Investigation 60:1280-1288.
Chisikovsky, J., Toto, P. and Gargiulo, A.
detection on bacterial plaque organisms.
dontology 53:6 88-6 92.

1982. Clq and C4
Journal of Perio-

Clagett, J.A. and Page, R.C. 1978. Insoluble immune complexes
and chronic periodontal diseases in men and the dog. Archives of
Oral Biology 23:153-165.

1971. Mechanisms involved in the deposition of
immune complexes in tissues. Journal of Experimental Medicine
134: 75s-89s.

Cochrane, C.G.

Colten, H.R., Borsos, T. and Rapp, H.J. 1968. Efficiency of the
effects of ionic strength.
first component of complement:
Journal of Immunology 100:808-813.

Cooper, N.R. 1969. Immunoadherence by the fourth component of
complement. Science 165:396-398.
Cooper, N.P and Mller-Eberhard, H.J. 1970. The reaction mechanism of human C5 in immune hemolysis. Journal of Experimental
Medicine 13 2:775-7 93.

Courts, F.J., Boackle, R.J., Fudenberg, H.H. and Silverman, M.S.
1977. Detection of functional complement components in gingival
fluid from humans with periodontal disease.
Research 56:3 27-331.

Journal of Dental

Craddock, P.R., Hebbel, R.P., White, J.G. and Jacob, H.S. 1977.
Complement-induced and Ca++ mediated granulocyte aggregation: a
previously unsuspected response of phagocytes. Clinical Research
25: 474a.
Damerau, B., Grnefeld, E. and Vogt, W. 1978. Chemotactic
effects of the complement derived peptides C3a, C3ai and C5a
(classical anaphylatoxin) on rabbit and guinea pig polymorphonuclear leukocytes. Archives of Pharmacology 305:181-184.
Daniels, C.A., Borsos, T., Rapp, H., Snyderman, R. and Notkins,
A.L. 1969. Neutralization of sensitized virus by the fourth
component of complement. Science 165:508-509.

-60-

DeCeulaer, C. 1980. Increased biosynthesis of complement components by cultured monocytes, synovial fluid macrophages and
synovial membrane cells from patients with rheumatoid arthritis.
Immunology 41: 37-43.

Dourmaskin, R.P, and P.atterson, S. 1975. Complement lesions in
cell membranes "from joint effusions of various types of arthritis. Inflammation 1:155-166.

,

Baker, C.J. and Kasper, D.L.
Edwards, M., Nicholson-Weller,
1980. The role of specific antibody in alternative complement
pathway-mediated opsonophagocytosis of Type III, Group B streptococcus. Journal of Experimental Medicine 151:1275-1287.
Ehlenberger, A.G. and Nussenweig, V. 1975. Synergy between
receptors for Fc and C3 in the induction of phagocytosis by human
monoytes and neutrophils. Federation Proceedings 34:854.

Ellis, LA. and Felix-Davies, D, 1959. Serum complement, rheumatoid factor, and other serum proteins in rheumatoid disease and
systemic lupus erythematosus. Annals of the Rheumatic Diseases
18:215-224.

Evans, PT., Spaeth, S. and Mergenhagen, S.E. 1966. Bacteriocidal antibody in mammalian serum to obligatory anaerobic gram
negative bacteria. Journal of Immunology 97:112-179.
Fearon, D.T., Austen, K.F. and Ruddy, S. 1973. Formation of a
hemolytically active cellular intermediate by the interaction
between properdin factors B and D and the activated third component of complement. Journal of Experimental Medicine 138:13051313.
Fearon, D.T. and Austen, K.F. 1975. Properdin: binding to C3b
and stabilization of the C3b-dependent C3 convertase. Journal of
Experimental Medicine 142:856-863.
Fearon, D.T. and Austen, K.F. 1977. Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanism.
Proceedings of the National Academy of Sciences of the United
States of America 74:1683-1687.
Fearon, D.T. 1979. Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from
human erythrocyte membrane. Proceedings of the National Academy
of Sciences of the United States of America 76:5867-5871.
Fearon, D.T., Ruddy, S., Schur, P. and McCabe, W.R. 1975. Activation of the properdin pathway of complement in patients with
gram negative bacteria. New England Journal of Medicine
292: 937-940.

-61-

Franco, ;UE. and Schur, P.H. 1971. Hypocomplementemia in rheumatoid arthritis. Arthritis and Rheumatism 14:231-238.

Frank, PM. and Cimasoni, G. 1972. Electron microscope study of
acid phosphatases in gingival fluid. Journal of Dental Research
51:852.

Frank, R.M. 1980. Bacterial penetration in the apical pocket
wall of advanced human periodontitis. Journal of Periodontal
Research 15:563-573.
Fujita, T., Gigli, I., and Nussenzweig, V. 1978. Human C4binding protein II. Role in proteolysis of C4b by C3b-inactivatot. Journal of Experimental Medicine 148:1044-1051.

Gabay,

P, Micheli, A. and Fallet, G.H. 1975. Behavior of
synovial complement C3 and C4 components in inflammatory and
degenerative joint diseases, before and after synoviorthesis.
Annals of the Rheumatic Diseases 34:166-170.
Genco, R., Mashimo, P., Krygier, G. and Ellison, S. 1974. Antibody-mediated effects on the periodontium. Journal of Per iodontology 45:330-337.

Gerard, C. and Hugli, T.E. 1979. Anaphylatoxin from the fifth
component of porcine complement: purification and partial chemJournal of Biological Chemistry
ical _characterization.
25 4: 63 46-63 51.

Gerard, C., Chenoweth, D.E. and Hugli, T.E. 1981. Response of
human neutrophils to C5a: a role for the oligosaccharide moiety
of human C5a des Arg-74 but not of C5a in biologic activity.
Journal-of Immunology 127:1978-1982.
Ghebrehiwet, B. and Mller-Eberhard, FJ. 1979. C3e: an acidic
fragment of human C3 with leukocytosis-inducing activity. Journal of Immunology 123:616-621.
1981. Clq inhibitor (Clq INH): functional proGhebrehiwet,
perties and possible relationship to a lymphocyte membrane-associated Clq precipitin. Journal of Immunology 126:1837-1842.

Gigli, I. and Nelson, R.A. 1968. Complement dependent immune
phagocytosis. I. Requirements for Cl, C4, C2, C3. Experimental
Cell Research 51: 45-67.
Gigli, I., Fujita, T. and Nussenzweig, V. 1979. Modulation of
the classical pathway C3 convertase by plasma proteins C4 binding
protein and C3b inactivator. Proceedings of the National Academy
of Sciences of the United States of America 76:6596-6660.

-62-

Glovsky, M. and Fudenberg, H.H. 1970. Reduced complement activity in sera of patients with Waldenstrom’s macroglobulinemia.
Journal of Immunology 104:1072-1078.

Gocke, D.J., Morgan, C., Lockshin, M., Hsu, K., Bombardierlis, S.
and Christian, ,C.B. 1970. Association between txiarteritis and
Australia antigen. Lancet 2:1149-1153.
Goldstein, I.M. and Weissman, N.G. 1974. Generation of C5derived lysosomal enzyme-releasing activity (C5a) by lysates of
leukocyte lysosomes. Journal of Immunology 113:1583-1588.

Goldstein, I.M., Kaplan, H.B., Radin, A. and Frosch, M. 1976.
Independent effects of IgG and complement upon human polymorphonuclear leukocyte function. Journal of Immunology 117:12821287.
Gorski, J,P., Hugli, T.E. and Mller-Eberhard, H.J. 1979. C4a:
the third anaphylatoxin of the human complement system. Proceedings of the National Academy of Sciences of the United States of
America 76:5299-5302.

Gtze, O. and Mller-Eberhard, FJ. 1976. The alternative pathway of complement activation. Advm’s in Immunology’ 24:1-35.
Gtze, 0., Bianco, C. and Cohn, Z.A. 1979. The induction of
macrophage spr,eading by Factor B of the properdin system.
Journal of Experimental Medicine 149:372-386.
Gustafsson, G.T. and Nilsson, M.I. 1961. Fibrinolytic activity
Proceedings of the Society for
in fluid from gingival crevice.
Experimental Biology and Medicine i06:277-280.
Hadding, U., Hamuro, J. and Bitter-Suermann, D, 1978. Biological activities of the purified Ba fragment derived from guinea
pig Factor B of the alternative pathway (abstract). Journal of
Immunology 120:1776.
Hara, K. and Le, L 196 9. Carbohydrate components of gingival
exudate. Journal of Periodontal Research 4:202-207.
Hawley, C. and Falkler, W. 1977. Anticomplementary activity of
_F.u.sobacterium ;X).lymrphum in normal and C4-deficient sources of
guinea pig complement. Infection and Immunit 18:124-129.
Hedberg, H. 1964. The depressed synovial complement activity in
adult and juvenile rheumatoid arthritis. Acta Rheumatologica
Scandinavica 10:109-127.

-63-

Hinz, C.F., Jr., Jordan, W.S., Jr. and Pillemer, L. 1956. The
properdin system and immunity. IV. The hemolysis of erythro
cytes from patients with paroxysmal nocturnal hemoglobinuria.
Journal of Clinical Investigation 35: 453-457.
Hirsch, R.L., Winkelstein, J.A. and Griffen, D.E. 1980. The
role of complement in viral infections. III. Activation of the
classical and alternative complement pathways by Sindbis virus.
Journal of Immunology 124:2507-2516.
Hodgson, H.J.F., Potter, B.J. and Jewell, D.P. 1977. C3 metabolism in ulcerative colitis and Crohn’s disease. Clinical and
Experimental Immunology 28:490-495.

Hollander, J.L., McCarty, D.J. Jr., Astorga, G. and CastroMurillo, E, 1965. Studies on the pathogenesis of rheumatoid
joint inflammation: I. The "R. Cell" and a working hypothesis.
Annals of Internal Medicine 62:271-280.
Holmberg, K. and Killander, J. 1971. Quantitative determination
of immunoglobulins (IgG, IgA and IgM) and identification of IgAtype in the gingival fluid. Journal of Periodontal Research
6:1-8.

Hunder, G.G. and McDuffie, F.C. 1973. Hypocomplementemia in
rheumatoid arthritis. American Journal of Medicine 54: 461-472.
Hugli, T.E.

1975.

Human anaphylatoxin (C3a) from the third
Journal of Biological Chemistry

component of complement.
250: 82 93-83 01.

Hugli, T.E. and Mller-Eberhard, }J. 1978.
and c5 Advances in Immunology 26:1-53.

Anaphylatoxins: C3a

Hunder, G., McDuffie, F. and Mullen, B. 1977. Activation of
complement components C3 and Factor B in synovial fluids. Journal of Laboratory and Clinical Medicine 89:160-171.
Hunder, G., McDuffie, F. and Clark, R. 1979. Consumption of C3
via the classical and alternative complement pathways by sera and
synovial fluids from patients with rheumatoid arthritis. Journal
of Clinical and Laboratory Immunology 2:26 9-273.
Hunsicker, L.G., Ruddy, S., Carpenter, C,B., Schur, P.H. Merrill,
J.P., Mller-Eberhard, H.J. and Austen, K.F. 1972. Metabolism
of third complement component (C3) in nephritis. Involvement of
the classic and alternate (properdin) pathways for complement
activation. New England Journal of Medicine 287: 835-840.

-64-

Hyslop, N.E., Dourmashkin, R.R., Green, N.M. and
1970. The fixation of complement and the activated
nent (Cl) of complement by complexes formed between
divalent hapten... Journal of .Experimental Medicine

Porter, R.R.
first compoantibody and
131:783-802.

Ishikawa, H. and ziff, M. 1976. Electronmicroscopic observations of immun0reactive cells in the rheumatoid synovial membrane. Arthriis and Rheumatism 19:1-14.

Johnson, U., Ohlsson, K. and Olsson, I. 1976. Effects of granulocyte neutral proteases on complement components. Scandinavian
Journal of Immunology 5:421-426.
Kahnberg, K.E., Lindhe, J. and Attstr6m, R. 1976. The role of
complement in initial gingivitis. I. The effect of decomplementation by cobra venom factor. Journal of Periodontal Research
ii: 26 9-27 8.
Kahnberg, K.E., Lindhe, J. and Attstrm, R. 1977. The effect of
decomplementation by carragheenan on experimental initial gingivitis in hyperimmune dogs. Journal of Periodontal Research
12: 479-490.
Kaplan, R.A., Curd, J.G., Deheer, D., Carson, D.A., Pangburn, M.,
Mller-Eberhard, H.J. and Vaughan, J. 1980. Metabolism of C4
and Factor B in Rheumatoid Arthritis relation to rheumatoid
factor. Arthritis and Rheumatism 23: 911-920,

Kazatchkine, M.D., Fearon, D.T. -and Austen, K.F. 1979. Human
alternative complement pathway: membrane-associated sialic acid
regulates the competition between B and beta-l-H for cell-bound
C3b. Journal of Immunology 122:75-81.

Ker r, M.A. 1980. The human complement system: assembly of the
classical pathway C3 convertase. Biochemical Journal 189:173.
Klaus, G.G. and Humphrey, J.L 1977. The- generation of memory
cells. I. The role of C3 in the generation of B memory cells.
Immunology 33:31-40.
Klemperer, M.R., Rosen, F.S. and Donaldson, V.H. 1969. A polypeptide derived from the second component of human complement
(C2) which increases vascular permeability. Journal of Clinical
Investigation 48: 44a-45a.

H.R., Villiger, W. and Isliker, H. 1975. Chemical
human Clq prepared by differanalYSiS and electron microscopyofofImmunology
5:78-82.
ent methods. European Journal

Knobel,

-65-

Koffler, D., Agnello, V., Thoburn, R. and Kunkel, H.G. 1971.
1971. Systemic Lupus Erythematosus. Prototype of immune complex
nephritis in man. Journal of Experimental Medicine 13 4:169s179s.

Kolb, W.P. and Mller-Eberhard, LJ. 1975. The membrane attack
mechanism of complement: isolation and subunit composition of the
C5b-9 complex. Journal of Experimental Medicine 141:724-735.

Krasse, B. and Egelberg, J. 1962. The relative proportions of
sodium, potassium and calcium in gingival pocket fluid. Acta
Odontologica Scandinavica 20:143-152.

Kreutzer, D.L., Claypool, W.D., Jones, M.L. and Ward, P.A. 1979.
Isolation by hydrophobic chromatography of the chemotactic factor
in activators from human serum. Clinical Immunology and Immunopathology 12:162-176.
Krick, H., DeHeer, D.H. Kaplan, R.A., Arroyave, C.M. and Vaughan,
J.H. 1978. Metabolism of Factor B of serum complement in rheumatoid arthritis. Clinical and Experimental Immunology 34:1-9.

Lake, A.M., Stitzel, A., Urmson, J., Walker, W.A. and Spitzer,
R.E. 1979. Complement alterations in inflammatory bowel disease. Gastroenterology 76:137 4-1379.
Lally, E.T., Baehni, P.C. and McArthur, W.s. 1980 Local immunoglobulin synthesis in periodontal disease, journal of Periodontal Research 15:159-164.

Lally, E., McArthur, W. and Baehni, P. 1982. Biosynthesis of
complement components in chronically inflamed gingiva. Journal
of Periodontal Research 17:257-262.

Lambert, P.H., Nydegger, U.E., Perrin, L.H., McCormick, J., Fehr,
K. and Miescher, P. 197 5. Complement activation in seropositire and seronegative rheumatoid arthritis. I-Clq binding
capacity and complement breakdown products in serum and synovia
fluid. Rheumatology 6:52-59.
Law, S.K., Fearon, P.T. and Levine, R.P. 1979. Action of the
Journal of Immunology
C3b-inactivator on cell-bound C3b.
122: 759-7 65.

Law, S.K., Lichtenberg, N.A., Holcombe, F.H. and Levine, R.P.
1980. Interaction between the labile binding sites of the fourth
(C4) and fifth (C5) human complement proteins and erythrocyte
cell membranes. Journal of Immunology 125:634-639.

-66-

Lepow, I.H., Naff, G.B., Todd, E.W., Pensky, J. and Hinz, C.F.
1963. Chromatographic resolution of the first component of human
complement into three activities. Journal of Experimental Medicine 117:983-1008.

Lesavre, P. andMSllerEberhard, FJ. 1978. Mechanism of action
of Factor D of the alternative complement pathway. Journal of
Experimental Medicine 148:1498-1509.

Lewis, G.K., Ranker, R. and Goodman, J.W. 1977. Complementdependent and -independent pathways of T cell-B cell cooperation.
Journal of Immunology

i18:1744-1747.

Lint, T.F., Behrends, C.L. and Gewurz, H. 1977. Serum lipoproteins and C567-INH activity. Journal of Immunology I19:883-888.

,
I.

H. and Silness, J. 1963.
Prevalence and severity.

Periodontal disease in pregnancy.
Acta Odontologica Scandinavica

21: 523-551.

McCabe, W.P 1973. Serum complement levels in bacteremia due to
New England Journal of Medicine
gram-negative organisms.
288:21-23.
McDuffie, F.C., Sams, W.M. Jr., Maldonado, J.E., Andreini, P.H.,
Conn, D.L. and Samayoa, E.A. 1973. Hypocomplementemia with
cutaneous vascuiitis and arthritis. Possible immune complex
syndrome. Mayo Clinic Proceedings 48:340-348.

Mackler, B.F., Waldrop, T.C., Schur, P., Robertson, P.B. and
Levy, B.M. 1978. IgG subclasses in human periodontal disease.
I. Distributon and incidence of IgG subclass bearing lymphocytes
and plasma cells. Journal of Periodontal Research 13:109-119.

Mann, W.B. and Stoffer, H.P 1964. The identification of protein components in fluids from gingival pockets. Periodontics
2:263-266.
Mansheim, B.J., Stenstrom, M.L., Low, S.B. and Clarke, W.B.
1980. Measurement of serum and salivary antibodies to the oral
pathogen Bac.t.e..oides asaccha.rolyt.cu.s in human subjects.
Archives of Oral Biology 25:553-557.

,

Marcus, R.L., Shin, H.S. and Mayer, M.M. 1971. An alternative
complement pathway: C3 cleaving activity, not due to C42a on
endotoxic lipopolysaccharide after treatment with guinea pig
serum; relation to properdin. -Proceedings of the National Academy Sciences of the United States of America 68:1351-1354.

-67-

Medicus, R.G., Gtze, O., and Mller-Eberhard, H.J. 1976. The
serine protease nature of the C3 and C5 convertases of the classical and alternative complement pathway. Scandinavian Journal
of Immunology 5:I049-1055.

Medicus, R.G., Esser, A.F., Fernandez, H.N. and Mller-Eberhard,
LJ. 1980. Native and activated properdin: interconvertibility
and identity of amino- and carboxy-terminal sequences. Journal
of Immunology 124:602-606.
Menzel, J., Jungfer, H. and Gernsa, D. 1978. Contributions of
immunoglobulins M and G, complement, and properdin to the intracellular killing of Escheria 9.oli by polymorphonuclear leukocytes. Infection and Immunity 19:659-666.

Mergenhagen, S.E., DeAraujo, W.C. and Varah, E. 1965. Antibody
to Lept.otrichia buccalis in human sera. Archives of Oral Biology
10:29-33.

Mills, B.J., Beebe, D. and Cooper, N.R. 1979. Antibody independent neutralization of vesicular stomatitis by human complement.
II. Formation of VSV-lipoprotein complexes in human serum and
complement-dependent viral lysis. Journal of Immunology
123 : 2518-252 4.

Monahan, J.B. and Sodetz, J.M. 1981. Role of the beta subunit
in interaction of the eighth component of human complement with
the membrane-bound cytolytic complex. Journal of Biological
Chemistry 256:3258-3 262.
Muhlfelder, T.W., Niemetz, J., Kreutzer, D., Beebe, D., Ward,
P.;U and Rosenfeld, S.I. 1979. C5 chemotactic fragment induces
leukocyte production of tissue factor activity: a link between
complement and coagulation. Journal of Clinical Investigation

63:147-150.

Mller-Eberhard, H.J. and Lepow, I.H. 1965. C1 esterase effect
on activity and physicochemical properites of the fourth component of complement. Journal of Experimental Medicine 121:819833.
Mller-Eberhar d, FJ. 1977. Chemistry and function of the cornplement system. Hospital Practice 12:33-43.

Mller-Eberhard, LJ. and Schreiber, PD. 1980. Molecular biology and chemistry of the alternative pathway of complement.
Advances in Immunology 2 9:1-53.
Naff, G.B. and Ratnoff, O.D. 1968. The enzymatic nature of
C’Ir. Conversion of C’Is to C’I esterase and digestion of amino
acid esters by C’Ir. Journal of Experimental Medicine 128:5715 93.

-68-

Nagasawa, S., Ichiharar, C. and Stroud R.M. 1980. Cleavage of
C4b by C3b inactivator: Production of a nicked form of C4b, C4b’,
as an intermediate cleavage, product of C4b by C3b inactivator.
Journal of Immunology 125:57 8-582.
Nilsson, V.R., Tsai, C.C., McArthur, W.P. and Taichman, N.S.
1975. Activation of the complement system by Actinom_vces viscosus. Journal of Dental Research 54A:311.

Nilsson, U.R., Goultscin, J., Norman, M.E., Mapes, J.A.,
McArthur, W.P. and Taichman, N.S. 1977. Cleavage of the fifth
component of human complement (C5) in gingival crevice fluid and
saliva. Journal of Dental Research 56A:125.

Nisengard, R. and Jarrett, C-. 1976. Coating of subgingival
bacteria with immunoglobulin and complement. Journal of Periodontology 47:518-521.
Nisengard, R., Beutner, E., Neugeboren, N., Neiders, M. and
1977. Experimental induction of periodontal disease
with Ar thus-type reactions. Clinical Immunology and Immunopathology 8: 97-i04.

Asaro, J.

Nydegger, U.E., Zubler, PH., Gabay P, Joliat, G., Karagevrekis,
C., Lambert, P.H. and Miescher, P.A. 1977. Circulating complement breakdown products in patients with rheumatoid arthritis:
correlation between plasma C3d, circulating immune complexes and
clinical activity. Journal of Clinical Investigation 59:862-868.

O’Flaherty, J.T., Kreutzer, D.L. and Ward, P.A. 1977a. Neutrophil aggregation and swelling induced by chemotactic agents.
Journal of Immunology i19: 232-239.
O’Flaherty, J.T., Showell, H.J. and Ward, P.A. 1977b. Neutropenia induced by systemic infusion of chemotactic factors. Journal of Immunology 118:1586-1589.
Okada, H. and Silverman, M.S. 1979. Chemotactic activity in
periodontal disease. I. The role of complement in monocyte
chemotaxis. Journal of Periodontal Research 14:20-25.
Okuda, K. and Takazoe, I. 1980. Activation of complement by
dental plaque. Journal of Periodontal Research 15:232-239.
Olsson-Wennstrom, A., Wennstrm, J.J, and Mergenhagen, S.E.
1978. The mechanism of basophil histamine release in patients
with periodontal disease. Clinical and Experimental Immunology
33:166-173.

-69-

Page, R.C. and Schroeder, H.E. 1976. Pathogenesis of inflammatory periodontal disease. A summary of current work. Laboratory
Investigations 33:235-249.
Palestine, A. and Kiemperer, M. 1976. //! vivo activation of
proI:rdin Factor.B in normotensive bcteremic individuals. Jour.
nal of ImmunolOgy 117 : 7 03 -705.
Pangburn, M.K., Schreiber R.D. and Mller-Eberhard, H.J. 1977.
Human complement C3b inactivator isolation, characterization,
and demonstration of an absolute requirement for the serum protein beta-l-H for cleavage of C3b and C4b in solution. Journal
of Experimental Medicine 146:257-270.

Patters, M.P, Schenkein, H.; and Weinstein, A.

1979. A method
for detection of complement cleavage in gingival fluid. Journal
of Dental Research 58:1620-1624.

Payne, W.A., Page, PC. and Ogilvie, A.L. 1975. Histopathologic
features of the initial and early stages of experimental gingivitis in man. Journal of Periodontal Research 10:51-64.

Pekin, T.J., Jr. and Zvaifler, N.J. 1964. Hemolytic complement
in synovial fluid. Journal of Clinical Investigation 43:13721382.
Pepys, M.B. 19-;4. Role of complement in induction of antibody
production i__n vivo. Effect of cobra factor and other C3-reactive
agents on thymus-independent antibody responses. Journal of
Experimental Medicine 140:126-145.

Perrin, L.H., Lambert, P.H., Nydegger, U.E. and Miescher, P.
1973. Quantitation of C3PA (properdin factor B) and other complement components in diseases associated with a low C3 level.
Clinical Immunology and Immunopathology 2:16-27.
Perrin, IL, Lambert, P.HI and Miescher, P. 1975. Complement
breakdown products in plasma from patients with systemic lupus
erythematosus and patients with membranoproliferative or other
glomerulonephritis. Journal of Clinical Investigation 56:16576.
Perrin, L.H., Nydegger, rU.E., Zubler, R.H., Lambert, P.H. and
Miescher, P.A. 1977. Correlation between levels of breakdown
products of C3, C4, and properdin Factor B in synovial fluids
from patients with rheumatoid arthritis. Arthritis and Rheumatism 20:647-652.

Peters, D.K., Martin, A., Weinstein, A., Cameron, J., Barratt,
T.M,, Ogg, C.S. and Lachmann, P.J. 1972. Complement studies in
membrano-proliferative glomerulonephritis.
mental Immunology 11:311-320.

Clinical and Experi-

-70-

Pillemer, L., Blum, L., Lepow, I.H., Ross, O.A., Todd, E.W. and
Wardlaw, C. 1954. The properdin system and immunity: I.
Demonstration ad isolation of a new serum protein, properdin,
and its role in immune phenomena. Science 120:279-285.
Platt, D., Crosby, R.G. and Dalbow, M.H. 1970. Evidence for the
presence of immunoglobulins and antibodies in inflamed periodontal tissues. Journal of Periodontology 41:215-222.

Podack,-E.R., Biesecker, G., Kolb, W.P. and Mller-Eberhard, H.J.
1978a. The C5b-6 complex: reaction with C7,C8,C9. Journal of
Immunology 121: 484-490.

Podack, E.P, Kolb, W’P. and Mller-Eberhard, H.J. 1978b. The
C5b-6 complex: formation, isolation, and inhibition-of its activity by lipoprOtein and the S-protein of human serum. Journal of
Immunology 120:1841-1848.

Press,-E.M. and Gagnon, J. 1981. Human complement component C4:
Structural studies on the fragments derived from C4b by cleavage
with C3b inactivator. Biochemical Journal 199:351-357.
Raisz, L.G., Sandberg, A.L., Goodson, J.M., Simmons, H.A. and
Mergenhagen, S.E. 197 4. Complement-dependent stimulation of
prostaglandin synthesis and bone resorption. Science 185:789791.

Ratnoff, O.D. and LeP0W, I.H. 1957. Some properties of an
esterase derived from preparations of the first complement component. Journal of Experimental Medicine 106: 327-3 43.
Reid, K.HM. 1983. -Proteins involved in the activation and control of the two pathways of human complement.
Biochemical
Society Transactions 11:1-12.
Reynolds, H.Y., Atkinson, J.P., Newball, H.H. and Frank, M.
1975. Receptors for immunoglobulin and complement on human alveolar macrophages. Journal of Immunology i14:1813-1819.

Riethmuller, G., Meltzer, M., Franklin, E., and Meischer, P.A.
1966. Serum complement levels in patients with mixed (IgM-IgG)
cryoglobulinaemia. Clinical and Experimental Immunology 1:337339.
Ross, G.D., Polley, M.J., Rabellino, E. and Grey, H.M. 1973.
Two different complement receptors-on human lymphocytes: one
specific for C3b and one specific for C3b inactivator-cleaved
C3b. Journal of Experimental Medicine 138:798-811.

-71-

Rother, K. 1972. Leukocyte mobilizing factor: a new biological
activity derived from the third component of complement.
European Journal of Immunology 2:550-558.
Ruddy, S., Britton,’ M.C., Schur, P.H. and Austen, K.F. 1969.
Complement componentsin synovial fluid. Activation and fixation
in seropositie rheumatoid arthritis. Annals of the New York
Academy of Science 16 8:161-172.
Ruddy, S. and Austen, K.F. 1970. The complement-system in
rheumatoid arthritis: I. An analysis of complement component
activities in rheumatoid synovial fluids. Arthritis and Rheumatism 13:713-723.

Ruddy, S., Everson, L.K., Schur, P.H., and Austen, K.F. 1971.
Hemolytic assay of the ninth complement component: elevation and
depletion in rheumatic diseases. Journal of Experimental Medicine 134:259s-275s.
Ruddy, S. and Colten, LP 1974. Rheumatoid arthritis. Biosynthesis of complement proteins by synovial tissues. New England
Journal of Medicine 190:1284-1288.
Ruddy, S., Carpenter, C.B., Chin, K.W., Knostman, J.N., Soter,
A., Gotze, D., Muller-Eberhard, H.J. and Austen, K.F. 1975a.
Human complement metabolism:
An analysis of 144 studies.
Medicine 54:165-178.

Ruddy, S., Fearon, D.T. and Austen, K.F. 1975b. Depressed
synovial fluid levels of properdin and properdin factor B in
patients with rheumatoid arthritis. Arthritis and Rheumatism

18:289-295.
Rutherford, B. and Schenkein, H. 1983. C3 cleavage products
stimulate release of prostaglandins by human mononuclear phagocytes /!
Journal of Immunology 130:874-877.

_.

Saglie, R., Newman, M.G., Carranza, F.A., Jr.., and Pattison, G.L.
1982. Bacterial invasion of gingiva in advanced periodontitis in
humans. Journal of Periodontology 53:217-222.

Sakurai, T., Fujita, T., Kono, I., Kabashima, T., Yamane, K.,
Tamura, N. and Kashiwagi, H. 1982. Complement-mediated solubilization of immune complexes in systemic lupus erythematosus.
Clinical and Experimental Immunology 48:37-42.

Sandberg, A.L., Wahl, S.M. and Mergenhagen, S.E. 1975. Lymphokine production by C3b-stimulated B cells. Journal of Immunology
115: 13 9-144.

-72-

Santoro, F., Lachmann, P.J., Capron, A. and Capron, M. 1979.
Activation of complement by Schistosoa mansoni schistosomula:
killing of parasites by the alternative pathway and requirement
of IgG for classical pathway, activation.
Journal of Immunology

123:1551-1557.

, Ferreira, A., Gigli, I. and Nussenzweig, V.
Scharfstein,
1978. Human C4-binding protein. Journal of Experimental Medici ne 14 8: 207-222.
Schenkein, H., Cianciola, L. and Genco, R.J. 1976. Complement
activation in gingival pocket fluid from patients with periodontosis and severe periodontitis.
Journal of Dental Research

55:B207.

and Genco, PJ. 1977a. Gingival fluid and serum
Schenkein,
in periodontal diseases. I. Quantitative study of immunoglobulins, _complement components, and other plasma proteins. Journal
of Periodontology 48:772-777.

Schenkein,

and Genco, PJ. 1977b. Gingival fluid and serum
in periodontal diseases. II. Evidence for cleavage of complement cmInents C3, C3 pr:ctivator (Factor B) and C4 in gingival
fluid Journal of Periodontology 48:778-784.

Schenkein, H. and Genco, P 1979. Inhibition of lymphocyte
biastogenesis by C3c and C3d. Journal of Immunology 122:11261133.
Schlossberg, A. and Ferrigno, P.D. 1971. A histological study
of the incidence of plasma cells and lymphocytes in human gingival tissues. Journal of Oral Medicine 26:99-105.

Schorlemmer, H.U, and Allison, A.C. 1976. Effects of activated
complement components on enzyme secretion by macrophages. Immunology 31:7 81-788.
Schur, P.H. and Sandson, J. 1968. Immunologic factors and
clinical activity in systemic lupus erythematosus. New England
Journal of .Medicine. 27 8:533-53 8.

Schwartz, J., Stinson, F. and Parker, R.B. 1972. The passage of
tritiated endotoxin across intact crevicular epithelium.
of Periodontology 43: 270-276.

Journal

Shelton, E., Yonemasu, K. and Stroud, PM.

1972. Ultrastructure
of the human component Clq. Proceedings of the National Academy
of Sciences of the United States of America 69:65-68.

Shillitoe, E.J. and Lehner, T. 1972. Immunologlobulins and
complement in crevicular fluid, serum, and saliva in man.
Archives of Oral Biology 17:241-247.

-73-

Shiraishi, S. and Stroud, R.M. 1973. Cleavage products of C4b
produced by enzymes in human serum. Immunochemistry 12:935-939.
Shivers, B.R., Bridges, R.B., Kenney, E.B. and Bryant, A.W.
1974. The effect of..polysaccharides on complement activity.
Journal of lntal Research 53A:501.
Siegel, J., Claus, D. and Retras, K. 1976. Interaction of Creactive protein (CRP) and Cl (abstract). Federation Proceedings

35:49.

Silness, J. and Le, L 1964. Periodontal disease in pregnancy.
II. Correlation between oral hygiene and periodontal condition.
Acta Odontologica Scandinavica 22:121-135.
Sim, R.B. and Reboul, A. 1981. Preparation and properties of
human Cl inhibitor. Me’od in Enzymolog 80:43-54.
Sjoholm, A.G. and Laurell, A.B. 1973. Conversion of the fourth
complement component studied by crossed immunoelectrophoresis.
Clinical and Experimental Immunology 14:515-529.

Spitzer, R.E., Vallota, E.H., Forristal, J., Sudora, E., Stitzel,
A., Davis, N.C. and West, C.D. 1969. Serum C3 lytic system-in
patients with glomerulonephritis. Science 164:436-437.

Stastny, P. and Ziff, M. 1968. Circulating-cold-insoluble complexes and complement levels in systemic lupus erythematosus
(SLE). Arthritis and Rheumatism ii:512.

Stastny, P. and Ziff, M. 1969. Cold-insoluble complexesand
complement levels in systemic lupus erythematosus. New England
Journal of Medicine 2 80:1376-13 81.
Takahashi, M., Kawachi-Takahashi, S. and Matsnura, M. 1975.
Interaction of collagen with serum complement:_ inhibition of
complement-mediated hemolysis. International Archives of Allergy
and Applied Immunology 48:642-652.

Takahashi, M., Takahashi, S. and Hirose, S. 19 80. Solubilization of antigen-antibody complexes: a new function of complement
as a regulator of immune reactions. Progress in Allergy 27:134166.

Tanimoto, K., Cooper, N.R., Johnson, J.S. and Vaughan, J.H.
1975. Complement fixation by rheumatoid factor. Journal of
Clinical Investigation 55: 437-445.

-74Taylor, J.C., Crawford,
degradation of the third
human leukocyte elastase
fragments. Biochemistry

I.P. and Hugli, T.E. 1977. Limited
component (C3) of human complement by
(HLE): partial characterization of C3
16:3390-3396.

Tojo, T. and Fr.iou, G.L. 1968. Lupus nephritis: varying complement-fixing properties of immunoglobulin antildies to antigens
of cell nuclei. Science 161:904-906.

Toto, P.D., _Lin, L. and Gargiulo, A. 1978a Identification of
C3a, IgG, IgM in inflamed human gingiva. Journal of Dental
Research 57:696.

Toto, P.D., Lin, L. and Gargiulo,
complement in human periodontitis.

49:631-634.

1978b. Immunoglobulins and
Journal of Periodontology

Townes, A.S., Stewart, C.R., Jr. and Osler, A.G. 1963. Immunologic studies of systemic lupus erythematosus: II. Variations of
nucleoprotein-reactive gamma globulin and hemolytic serum complement levels with disease activity. Johns Hopkins Medical Journal
112: 202-219.

Townes, S. and Marcus, PL.
of rheumatoid synovial fluid.

31:393-401.

1972-

Complement-fixing activity
Annals of the Rheumatic Diseases

Vaughan, J.H., Morgan E.S. and Jacox, R.R. 1968. Role of gamma
globulin complexes in rheumatoid arthritis. Transactions of the
Association of American Physicians 81:231-238,

Versey, J.M.B., Hobbs, J.P and Holt, P.J.L. 1973. Complement
metabolism in rheumatoid arthritis: I. Longitudinal studies.
Annals of the Rheumatic Diseases 32:557-564.

Volanakis, J.E. and Kaplan, M.H. 197 4. Interaction of C-reactive protein complexes with the complement system: II. Consumption of guinea pig complement by CRP complexes: requirement_ for
human Clq. Journal of Immunology 113:9-17.
Ward P. and Cochrane, C.G. 1965.- Bound complement and immunologic injury of blood vessels. Journal of Experimetal Medicine

121:215-233.
Ward, P.A., Cochrane, C.G. and Mller-Eberhard, H.J. 1966. Further studies on the chemotactic factor of complement and-its
formation in
Immunology 11:141-153.

_.

Ward, P.A. and Newman, L.J. 1969. A neutrophil chemotactic
factor from human C5. Journal of Immunology 102:93-99.

-75-

Ward, P.A. and Becker, E.L.
Biology of leukotaxis.
1977.
Reviews of Physiology, Biochemistry and Pharmacology 77:125-148.
Weeke, B.

1973. Crossed-immunoelectrophoresis.

Scandinavian

Journal of Immunology (Suppl) 1:47-56.

Weinstein, A.,,. Peters, K., Brown, D. and Bluestone, R. 1972.
Metabolism of the third component of complement (C3) in patients
with rheumatoid arthritis. Arthritis and Rheumatism 15:49-56.
Weinstein, E. and Mandel, I.D.
sulcus. Periodontics 2:147.

1964.

The fluid of the gingival

Welsh, R.M., Jr. 1977. Host cell modification of lymphocytic
choriomeningitis virus and Newcastle disease virus altering viral
inactivation by human complement. Journal of ImmunologyllS:348
354.

Wennstrom, J., Heijl, L., Lindhe,-J. and Socransky, S. 1980.
Migration of gingival leukocytes mediated by plaque bacteria.
Journal of Periodontal Research

15:363-372.

West, C.D., McAdams, A.J., McConville, J.M., Davis, N.C. and
Holland, N.F 1965. Hypocomplementemic and normocomplementemic
persistent (chronic) glomerulonephritis; clinical and pathologic
characteristics. Journal of Pediatrics 67:1089-1112.

Whaley, K. 1980. Biosynthesis of the complement components and
the regulatory proteins of the alternative complement pathway in
human peripheral blood monocytes. Journal of Experimental Medicine 151:501-527.

Williams, R.C., Jr. and Law, D.H. 1958. Serum complement in
connective tissue disorders. Journal of Laboratory and Clinical
Medicine 52: 273-281.
Wilson, M.R., Arroyave, C.M., Miles, L., and Tan, E.M. 1977.
Immune reactants in cryoproteins: Relationship to complement
activation. Annals of the Rheumatic Diseases 36:540-548.
Winchester, R.J., Agnello, V. and Kunkel, H.G. 1969. The jointfluid gamma G-globulin complexes and their relationship to
intraarticular complement dimunition. Annals of the New York
Academy of Sciences 168:195-201.

Winchester, R.J., Agnello, V. and Kunkel, H.G. 1970. -Gamma
globulin complexes in synovial fluids of patients with rheumatoid
arthritiS: partial characterization and relationship to lowered
complement levels. Clinical and Experimental Immunology 6:689706.

-76-

Winkelstein, J.;u and Tomasz, A. 1978. Activation of the alternative complement pathway by pneumococcal cell wall teichoic
acid. Journal of Immunology 120:17 4-178.

Wyatt, R.J., McAdam, A.J., Forristal, F., Snyder, J., and West,
C.D. 1979. Glomerular, deposition of complement-control proteins
in acute and qhronic glomerulonephritis. Kidney International
16:505-512.

Yamamoto, K. and Gewurz, H. 1978. The complex of C5b and C6;
isolation, characterization, and identification of a modified
form of C5b consisting of three polypeptide chains.
Immunology 120: 2008-2015.

Journal of

Zvaifler, N.J. 1974. Rheumatoid synovitis: an extravascular
immune complex disease. Arthritis and Rheumatism 17:297-305.

-77-

N

DEVIATION

ERROR

VALUE

VALUE

TIME 1

26

1.88

0.65

0.13

1

3

TIME 2

26

1.35

0.49

0.i0

1

2

N=I0

WILOOXON T = 0

p

<=

0.005

N

DEVIATION

ERROR

VALUE

VALUE

3

16

0.63

0.81

0.20

0

2

TIME 4

16

0.75

0.86

0.21

0

2

T]3

UNTIED N = 7

WILO0XON T = 10.5

a)

standard deviations, and standard errors are shown for
descriptive purposes only and were not used in the statistical

Means,

analyses.
b)

p= NSb

NS = not significant

p>

0.05)

LE1

-78-

GINIVAL

DEVIATION

ERROR

VAI/]E

VALUE

TIME 1

26

1.54

0.51

0.i0

1

2

TIME 2

26

1.35

0.49

0.I0

1

2

W]IEOMON T = 18

UNTIEDN= ii

Sm

N

DEVIATION

Sm
ERROR

VALUE

VALUE

TIME 3

16

1.12

0.34

0.09

1

2

TIME 4

16

1.25

0.45

0 .ii

1

2

WILCOXON T = 7
a)

Means,

b)

NS = not significant (p

UNTIED N = 6

standard deviations, and standard errors are shcm for
descriptive purposes only and were not used in the statistical
analyses.

>

0.05)

LE2

-79-

N

DEVIATION

ERROR

VALUE

VALUE

TIME 1

26

0.81

0.40

0.08

0

1

TIME 2

26

0.73

0.45

0.0 9

0

1

UNTIED N = 8

WILOOXON T = 13.5

N

DION

ERROR

V

VALUE

TIME 3

16

0.50

0.52

0.13

0

1

TIME 4

16

0 63

0.50

0 13

0

1

UNTIED N = 6

WILCOXON T = 7

standard deviations, and standard errors are shown for
descriptive purposes only and were not used in the statistical
analyses.

a)

Means,

b)

NS = not significant (p

>

0.05)

-80-

( E, I--ITIVE)

N

TIME 1

26

TIME 2

26

VALUE

DEVIATION

ERROR

0.43

0.08

0

o.4o

0.08

o

ERROR

VALUE

VALUE

0.23

1

UNTIED N = 3

WILfDXON T = 2

N

DEVIATION
TIME 3

16

0

0

0

0

0

TIME 4

16

0.13

0.34

0.09

0

1

UNTIED N = 2

WILO3XONT= 0

standard deviations, and standard errors are shown for
descriptive purposes only and were not used in the statistical
analyses.

a)

Means,

b)

NS = not significant (p

>

0.05)

LE4

-81-

N

MEAN
VALUE DIFF

MEAN MIN
VALUE

MAXIM[

TIME 1

26

6.38

4

9

TIME 2

26

6.46

4

9

0.08

t = 0.53

MEAN
MAXI
VALUE DIFFERENCE

MEAN MINIMUM
VALUE

TIME 3

16

5.81

4

8

TIME 4

16

5.31

4

7

0.50

t = 2.74

b)

NS = not significant (p

df=15

>

0.05)

TBLE 5

0.15

p = 0.60 (NSb)

df=25

N

S%DARD ERRCR
OF DIFFERENCE

ST ERRCR
OF DIFFERENCE

0.18

p = 0.015

-82-

N

MEAN MINIMUM
VALUE

MAE[MHM

VAIb

TIME I

26

5.38

1

9

TIME 2

26

5.19

I

9

MEAN
DIFFE

STANDARD ERRCR
OF DIFFERENCE

0.19

0.17

p = 0.26 (NSb)

df=25

t = 1.15

N

MEAN
MAXIMUM
VALUE DIFFERENCE

MEAN MINIML
VALUE

TIME 3

16

6.00

4

9

TIME 4

16

5.38

3

8

0.62

df = 15

t = 3.49

b)

NS = not significant (p

>

0.05)

LE6

STANDARD ERRCR
OF DIFFER%?

0.18

p = 0.0034

-83-

O C3 (RION

+

N

MEAN MINIMUM
VALUE

MEAN
MAXIMUM
VALUE DIFFERENCE

TIME i

26

78.2

20.8

i00.0

TIME 2

26

62.2

0

i00.0

16.0

VATE

VAT/E

TIME 3

16

51.4

0

I00.0

TIME 4

16

39.4

0

87.3

t = 1.03
b)

NS = not significant (p

df=15

>

0.05)

8.4

p = 0.07 NSb)

df = 25

t = 1.90

ERROR
OF DIFFERENCE

DIFFERENCE

OF DIFFERENCE

12.0

II.7
p = 0.32 NSb)

-84-

N

DEVIATION

ERROR

VALUE

VALUE

TIME 1 (PRE)

37

1.76

0.60

0.I0

1

3

TIME 4 (POSg)

37

0.95

0.74

0.12

0

2

WILCOXON T = 6.5
a)

UNTIED N = 22

p

<= o.oos

Means, standard deviations, and standard errors are shown for
descriptive purposes only and were not used in the statistical
analyses.

-85-

N

DEVIATION

ERROR

VALUE

VALUE

TIME 1 (PRE)

37

1.54

0.51

0.08

1

2

TIME 4 ()

37

i.II

0.31

0.05

1

2

WILCOXON T = 9.5
a)

UNTIED N = 18

Means,

p

<=

0.005

standard deviations, and standard errors are shown for
descriptive purposes only and were not used in the statistical
analyses

BLE 9

-86-

N

DEVIATION

ERROR

VALUE

VALUE

TIME 1 (PRE)

37

0.86

0.35

0.06

0

1

TIME 4 (POST)

37

0.41

0.50

0.08

0

1

WILa)XCN

a)

T = 22

UNTIED N= 21

Means,

p

<=

0.005

standard deviations, and standard errors are sh(mm for
descriptive purposes only and were not used in the statistical
analyses

BLE I0

-87-

SHPRUI
(0-, 1=POSITIVE)

N
DEVIATION

ERRCR

VALUE

VALUE

TIME 1 (PRE)

37

0.22

0.42

0.07

0

1

TIME 4 (POST)

37

0.05

0.23

0.04

0

1

WILO0XON T = 0

a)

p

<=

0.025

Means, standard deviations, and standard errors are shown for
descriptive purposes only and were not used in the statistical
analyses.

-88-

N

TIME 1 (PRE)

MEAN MINIMUM
VALUE

MEAN
MAXIMUM
VALUE DIFFERENCE

37

6.32

4

9

TIME 4 (POST) 37

5.05

3

9

STANII%RD ERRCR
OF DIFFERENCE

0.25

i .27

t = 5.02

df=36

p

<=

0.O0005,

-89-

VALUE DIFFERENCE

TIME 1 (PRE)

37

5.65

1

TIME 4 (POST) 37

4.84

1

t = 4.82

OF DIFF

9

p

<= O. 00005

-90-

N

TIME 1 (PRE)

37

TIME 4 (P(35T) 37
t = 2.13

MEAN MINIMUM
VALUE

MEAN
MAXI
VALUE DIFFERENCE

985

0

4536

1675

80

6525
df=36

STANDARD ERROR
OF DIFFERENCE

0.040

-91-

N

TIME i (PRE)

37

TIME 4 () 37
t = 3.35

MEAN MINIM[R
VALUE

MEAN
MAXIMUM
VALUE DIFCE

1580

186

5350

904

0

2806
df=36

STANDARD ERRCR
OF DIFFERenCE

p = 0.0019

-92-

(cl[ + cc])

N

TIME 1 (PRE)

MEAN MINIMUM
VALUE

MEAN
MAXI
VALUE DICE

37

70.0

12.5

I00.0

TIME 4 () 37

37.5

0

87.3

t = 5.19

df=36

STANDARD ERRCR
OF DICE

p

<=

0.00005

-93-

N

MEAN
MAXIMUM
VALUE DIFFERenCE

MEAN MINI
VALUE

37

382

0

1680

TIME 4 () 37

347

0

1755

TIME 1 (PRE)

35

df=36

t = 0.32
b)

NS = not significant (p

>

0.05)

STANDARD ERROR
OF DIFFERENCE

109

p = 0.75 (NSb)

-94-

B

N

TIME 1 (PRE)

MEAN
MAXIMUM
VALUE DIFFERENCE

MEAN MINIMUM
VALUE

37

125

0

777

TIME 4 (POST) 37

138

0

1287

t =-0.25

b)

NS = not significant (p

df=36

>

0.05)

STANDARD ERRCR
OF DIFFERENCE

p = 0.81 (NSb)

-95-

N

MEAN
MAXIMDM
VALUE DIFFERENCE

MEAN MINIM[
VALUE

37

1626

0

10545

TIME 4 () 37

1246

0

5760

TIME 1 (PRE)

STANII%RD ERRCR
OF DIFFERENCE

380

df=36

t = 1.09

b)

NS = not significant (p

>

0.05)

p = 0.28

(b)

-96-

FI I.

A photograph of a stained crossed-immunoelectrophoresis
gel of gingival fluid from an untreated site of periodontitis. GF=gingival fluid. The precipitates are
labelled.
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FIGURE 2.

A photograph of a stained crossed-immunoelectrophoresis
gel of gingival fluid from_ the same site as figure 1
after periodontal therapy. A reduction in C3c can be
observed. GF=gingival fluid. The precipitates are
labelled.

